



Programme
Thu 25 April 2013

Programme

Thursday 25 April 2013

GETTING IT RIGHT FIRST TIME

BIOLOGICS IN RA: A DEBATE

THURSDAY, 25 APRIL 2013, 07:30–08:30
HALL 5, THE ICC, BIRMINGHAM, UK

Chair: Professor Philip Conaghan, University of Leeds, UK

Current understanding of RA and its aetiology

How can the different MOAs of the biologics be used to deliver patient outcomes?

Professor Peter Taylor, Kennedy Institute, Oxford, UK

The latest data in the treatment of RA with biologic therapies

What do the latest head-to-head trials tell us about biologic therapies and their place in RA treatment?

Professor Rene Westhovens, University of Leuven, Belgium
Dr Maya H Buch, University of Leeds, UK

What do we know, where are we heading?

Getting it right first time, debating the facts

Chairman, Speakers & Panel

Organised and funded by



ORENCIA® (abatacept) PRESCRIBING INFORMATION

See Summary of Product Characteristics before prescribing.

PRESENTATION: 250 mg powder for concentrate for solution for IV infusion containing 250 mg abatacept per vial. Each ml contains 25 mg of abatacept, after reconstitution; 125 mg pre-filled syringe for SC injection. Each pre-filled syringe contains 125 mg of abatacept in 1 ml. **INDICATION:** Rheumatoid arthritis (IV infusion and SC pre-filled syringe). Treatment of moderate to severe active rheumatoid arthritis (RA), in combination with methotrexate, in adult patients who have responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a Tumour Necrosis Factor (TNF)-alpha inhibitor. A reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and methotrexate. See SmPC. **Polyarticular Juvenile Idiopathic Arthritis (pJIA) (IV infusion only):** Orenzia 250 mg powder for concentrate for solution for infusion is indicated for treatment of moderate to severe active pJIA in paediatric patients 6 years of age and older who have had an insufficient response to other DMARDs including at least one TNF inhibitor. **DOSAGE AND ADMINISTRATION:** Treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of RA. Orenzia 250 mg powder for concentrate for solution for IV infusion. Adults and elderly: Patients weighing < 60kg: 500mg (2 vials). Patients weighing ≥ 60kg: ≤ 100kg:

Treatment of pJIA: Paediatric patients, 6 to 17 years of age, weighing less than 75 kg: 10 mg/kg paediatric patients weighing 75 kg or more: to be administered adult dosage, not exceeding a maximum dose of 1,000 mg. See SmPC for details of reconstitution and administration as a 30 minute IV infusion. After initial administration, Orenzia should be given at 2 and 4 weeks, then every 4 weeks thereafter. Children: Use in children below 6 years of age is not recommended. Orenzia 125 mg solution for injection (SC pre-filled syringe) Adults and elderly: Treatment should be initiated with a loading dose using an intravenous infusion. Following this loading dose, the first 125 mg subcutaneous injection of Orenzia should be given within a day, then 125 mg subcutaneous injections once weekly. Patients who are unable to receive an infusion may initiate weekly injections of subcutaneous Orenzia without an intravenous loading dose.

427UK13PRO1069 Date of preparation: February 2013

Patients transitioning from Orenzia IV therapy to SC administration should administer the first subcutaneous dose instead of the next scheduled intravenous dose. Children: Administration in children below 18 years of age is not recommended. The continuation of treatment with abatacept should be re-assessed if patients do not respond within 6 months. **CONTRAINDICATIONS:** Hypersensitivity to the active substance or excipients. Severe and uncontrolled infections such as sepsis and opportunistic infections. **WARNINGS AND PRECAUTIONS:** Allergic Reactions: Caution in patients with a history of allergic reactions. Orenzia should be discontinued if a patient develops serious allergic or anaphylactic reaction. Infections: Caution should be exercised when considering the use in patients with a history of frequent infections, or underlying conditions which may prompt to infection. Treatment with Orenzia should not be initiated with patients with active infections until infections are controlled. Screening for tuberculosis and hepatitis B should be performed prior to therapy. Any patient who develops a new infection should be closely monitored and Orenzia should be discontinued if a patient develops a serious infection. Monitor patients for signs of infection when transitioning from TNF-antagonist to Orenzia. Co-administration of Orenzia with biologic immunosuppressive or immunomodulatory agents could potentiate the effects of abatacept on the immune system. Treatment with immunosuppressive therapy may be associated with progressive multifocal leukoencephalopathy (PML). Orenzia treatment should be discontinued if neurological symptoms suggestive of PML occur, and appropriate diagnostic measures initiated. Malignancies: The potential role of Orenzia in the development of malignancies is unknown. See SmPC. Elderly: Caution should be used when treating elderly patients due to a higher incidence of infections and malignancies in this patient group. Autoimmune processes: Theoretical risk of deterioration in autoimmune disease. Immunisation: Live vaccines should not be given simultaneously or within 3 months of discontinuation of Orenzia. See SmPC. **DRUG INTERACTIONS:** Concomitant therapy of Orenzia with a TNF-inhibitor is not recommended. No major safety issues were identified with the use of Orenzia in combination with sulfasalazine, hydroxychloroquine or leflunomide. **PREGNANCY AND LACTATION:** Do not use in pregnancy unless clearly necessary. Women should use contraception and not breast-feed during treatment and for up to 14 weeks after last dose treatment. **UNDESIRABLE EFFECTS:** In adult placebo-

controlled trials the following adverse drug reactions were reported. **Very Common (≥ 1/10):** upper respiratory tract infection including tracheitis, nasopharyngitis. **Common (≥ 1/100 to < 1/10):** Lower respiratory tract infection (including bronchitis), urinary tract infection, herpes simplex, rhinitis, pneumonia, influenza, leukopenia, headache, dizziness, paraesthesia, conjunctivitis, hypertension, flushing, blood pressure increased, cough, abdominal pain, diarrhoea, nausea, dyspepsia, mouth ulceration, aphthous stomatitis, vomiting, liver function test abnormal (including transaminases increased), rash (including dermatitis), alopecia, pruritus, pain in extremity, fatigue, asthenia, injection site reactions. **Uncommon (≥ 1/1,000 to < 1/100):** Tooth infection, onychomycosis, herpes zoster, sepsis, musculoskeletal infections, skin abscess, pyelonephritis, pelvic inflammatory disease, basal cell carcinoma, skin papilloma, thrombocytopenia, hypersensitivity, depression, anxiety, sleep disorder, migraine, dry eye, visual acuity reduced, vertigo, palpitations, tachycardia, bradycardia, hypotension, hot flush, vasculitis, blood pressure decreased, bronchospasm, wheezing, dyspnea, gastritis, increased tendency to bruise, dry skin, urticaria, psoriasis, arthralgia, amenorrhoea, menorrhagia, influenza like illness, weight increased. **Rare (≥ 1/10,000 to < 1/1,000):** Bacteraemia, gastrointestinal infection, lymphoma, lung neoplasm malignant, throat tightness. See SmPC for further details. **LEGAL CATEGORY:** POM **MARKETING AUTHORISATION NUMBER AND BASIC NHS PRICE:** Orenzia 250 mg concentrate for solution for infusion - EU/1107/389/001, 1 vial pack: £302.40 Orenzia 125 mg solution for injection - EU/1107/389/008, 4 pre-filled syringes with needle guard: £1209.60 **MARKETING AUTHORISATION HOLDER:** Bristol-Myers Squibb Pharma EEIG, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex UB8 1DH. Tel: 0800-731-1736 **DATE OF PREPARATION:** October 2012. Job No: 427UK12PM087

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Pharmaceuticals Ltd Medical Information on 0800 731 1736 or medical.information@bms.com.



Breakfast will be provided from 07:00

07.00 – 07.30

Industry supported symposium catering

07.30 – 09.00

Industry supported symposium: Bristol-Myers Squibb | Hall 5**Getting it Right First Time**

Biologics in RA: A Debate

*Chair: Prof Philip Conaghan, University of Leeds, Leeds***Current understanding of RA and its aetiology**

How can the different MOAs of the biologics be used to deliver patient outcomes?

*Prof Peter Taylor, Kennedy Institute, Oxford***The latest data in the treatment of RA with biologic therapies**

What do the latest head-to-head trials tell us about biologic therapies and their place in RA treatment?

*Prof Rene Westhovens, University of Leuven, Belgium**Dr Maya Buch, University of Leeds, Leeds***What do we know, where are we heading?**

Getting it right first time, debating the facts

Chairman, speakers and panel

09.00 – 10.30

Ageing and the musculoskeletal system | Hall 8b*Chairs: Dr Fraser Birrell, Newcastle University, Newcastle and Prof Eugene McCloskey, University of Sheffield, Sheffield***Aim:**

The ageing population and high prevalence of age associated musculoskeletal disease make it important that clinicians and researchers keep abreast of the latest research in this field

Outcome 1:

Delegates will understand the concept of healthy ageing

Outcome 2:

Delegates will know the state of the art of work with animal models and stem cells

Outcome 3:

Delegates will recognise the occurrence of age related musculoskeletal disease and the challenges inherent in clinical trials in the elderly

09.00

Musculoskeletal ageing: from epidemiology to clinical trials*Prof Cyrus Cooper, University of Southampton, Southampton*

09.30

Mouse models for mechanistic studies of skeletal muscle ageing*Dr Aphrodite Vasilaki, University of Liverpool, Liverpool*

10.00

Stem cells and ageing*Dr Illaria Belluantono, University of Sheffield, Sheffield*

09.00 – 10.30

Ask the experts | Hall 9

Chairs: Dr Benjamin Parker, University of Manchester, Manchester and Dr Sonia Panchal, Northampton General Hospital, Northampton

Aim:

To provide trainees with practical teaching and advice on the management of SLE

Outcome 1:

Delegates will be able to present and discuss difficult SLE cases

Outcome 2:

Delegates will have a better understanding of clinical presentation of SLE

Outcome 3:

Delegates will be able to discuss management issues in SLE with an expert panel

09.00

SLE

Prof Ian Bruce, University of Manchester, Manchester and Prof Anisur Rahman, University College London, London

09.00 – 10.30

Mortality in rheumatic disease | Hall 4

Chairs: Prof Gary Macfarlane, University of Aberdeen, Aberdeen and Dr Jennifer Hamilton, Queen Elizabeth Hospital, Gateshead

Aim:

To summarise the evidence on whether patients with specific rheumatic diseases experience excess mortality and if so to describe the specific causes of death in excess, possible mechanisms and relevance to management

Outcome 1:

To be able to describe the pattern of mortality associated with three musculoskeletal conditions

Outcome 2:

To understand the mechanisms underlying association with excess mortality

Outcome 3:

To understand the relevance of such patterns of excess mortality for managing patients with specific rheumatic diseases

09.00

Mortality in systemic sclerosis: a European perspective

Prof Ulf Müller-Ladner, Justus-Liebig University Giessen, Bad Nauheim, Germany

09.30

Co-morbidities in RA and their influence on premature mortality

Dr Nicola Gullick, King's College Hospital, London

10.00

Musculoskeletal pain and excess mortality: the story so far

Dr Kelvin Jordan, Keele University, Keele

**Twitter**

@RheumatologyUK
#Rheum2013

**LinkedIn Groups**

BSR
Rheumatology 2013

**Facebook**

The British Society for
Rheumatology

09.00 – 10.30

BSR/BHPR: Advanced practice in osteoarthritis | Hall 1

Chairs: Prof Philip Conaghan, University of Leeds, Leeds and Prof Michael Hurley, Kingston University and St George's, University of London, London

Aim:

This multidisciplinary session will provide delegates with an overview of how aspects of advanced practice e.g. gait analysis, diagnostic ultrasound can be incorporated into the management pathways for patients with OA. Delegates will be able to understand how adverse mechanics influence structure and function at key sites in the lower limb and the implications for OA.

Outcome 1:

Delegates will gain an insight into how research and clinical care can be integrated to impact positively on the care of patients with OA pathways for patients with symptomatic OA.

Outcome 2:**Outcome 3:**

Delegates will have a better understanding of how mechanical and imaging assessments impact on care pathways for patients with symptomatic OA.

09.00

The assessment of adverse mechanics in knee OA

Prof Martijn Steultjens, Glasgow Caledonian University, Glasgow

09.30

Amsterdam outpatient osteoarthritis clinic: integrating care and science for OA

Dr Martin van der Esch, Reade Rehabilitation Centre, Amsterdam, The Netherlands

10.00

The ULTRASCOT (ULTRAsound SCanning of Osteoarthritis in the Thumb) study: results and implications for practice

Mrs Mhairi Brandon, Glasgow Royal Infirmary, Glasgow

09.00 – 10.30

Oral abstracts: RA clinical | Hall 7

Chairs: Prof David Scott, King's College London, London and Dr Patrick Kiely, St George's Healthcare NHS Trust, London

09.00

Long-term outcomes of early RA patients initiated with adalimumab plus methotrexate compared with methotrexate alone following a targeted treatment approach

Prof Paul Emery, University of Leeds, Leeds

09.15

24 week results of a blinded phase 2B dose-ranging study of baricitinib, an oral JAK1/JAK2 inhibitor, in combination with traditional DMARDs in patients with rheumatoid arthritis

Prof Peter Taylor, University of Oxford, Oxford

09.30

Tocilizumab (TCZ) monotherapy compared with adalimumab (ADA) monotherapy in RA: results of a 24 week study

Prof Paul Emery, University of Leeds, Leeds

09.45

Head-to-head comparison of subcutaneous abatacept versus adalimumab in the treatment of rheumatoid arthritis: key efficacy and safety results from the AMPLE (abatacept versus adalimumab comparison in biologic-naïve RA subjects with background methotrexate) trial

Dr Michael Maldonado, Bristol-Myers Squibb, Princeton, USA

10.00

What happens to ACPA positive patients without clinical synovitis?

Dr Chadi Rakieh, University of Leeds, Leeds

10.15

Interferon gene expression signature in neutrophils from RA patients pre and post anti-TNF therapy

Dr Helen Wright, University of Liverpool, Liverpool

09.00 – 10.30

SIG: Heritable disorders of connective tissue | Hall 10

Chair: Prof Rodney Grahame, University College Hospital, London and Prof Howard Bird, University of Leeds, Leeds

Aim: To familiarise BSR and BHPR members and guests with the work of Ehlers-Danlos National Diagnosis Service (funded by the National Commissioning Group) and to assess its progress since its inception in 2010

Outcome 1: Acquisition of knowledge of the role of molecular genetic testing in the differential diagnosis of the rare forms of EDS

Outcome 2: Acquisition of knowledge of Novel COL3A1 collagen mutations and their EDS phenotypes

Outcome 3: Acquisition of knowledge of rheumatological complications in rare genetic syndromes

- 09.00 **New observations on EDS in South Africa**
Prof Peter Beighton, University of Cape Town, South Africa
- 09.15 **Novel COL3A1 mutations in Vascular EDS phenotypes (the London experience since 2009)**
Prof Mike Pope, Northwick Park and St Mark's Hospitals, Harrow
- 09.30 **The EDS National Diagnostic Service in 2013**
Dr Glenda Sobey, Sheffield Children's Hospital, Sheffield
- 09.45 **Molecular Genetic Diagnosis in EDS**
Dr Mandy Nesbitt, Sheffield Children's Hospital, Sheffield
- 10.00 **Rare Mendelian disorders and Joint Hypermobility Syndrome**
Dr Anthony Vandersteen, Northwick Park and St Marks Hospitals, Harrow
- 10.15 **Question and answer session**

09.00 – 10.30

SIG: Sjögren's | Hall 11

Chair: Dr Elizabeth Price, Great Western Hospital, Swindon

Aim: To update and educate rheumatologists on the practical management of and recent advances in Sjögren's syndrome

Outcome 1: Update management of dry eye in Sjögren's syndrome

Outcome 2: Update management of dry mouth in Sjögren's syndrome

Outcome 3: Update on new therapeutic advances in the systemic management of Sjögren's syndrome

- 09.00 **The modern management of dry eye in Sjögren's syndrome**
Miss Saaesha Rauz, University of Birmingham, Birmingham
- 09.25 **The modern management of dry mouth in Sjögren's syndrome**
Mr John Hamburger, University of Birmingham, Birmingham
- 09.50 **New therapeutic approaches for Sjögren's**
Dr Francesca Barone, University of Birmingham, Birmingham

09.00 – 10.30

BHPR: Introducing cognitive behavioural approaches to rheumatic disease: top tips and tools for clinic Hall 8a | Places are limited to 60 attendees for this session and will be allocated on a first come, first served basis

Aim:

To introduce rheumatology clinicians to basic cognitive-behavioural CB techniques and tools that can be readily integrated into routine clinical encounters, provide opportunities to observe demonstrations, and for delegates to practice the skills in small groups

Outcome 1:

Learn how to work on a formulation diagram with patients to identify and understand the links between thoughts, feelings and behaviours, and how they relate to symptoms

Outcome 2:

Learn how to support patients to set effective goals by identifying components of SMART goals; including how and where to start, follow up and build on goals, and suggestions for constructive responses when goals are not achieved

Outcome 3:

Learn how to use Socratic questioning to unpick behavior patterns in relation to activity, sleep and rest; and review self-monitoring records with patients to identifying where changes can be made and further support is needed

09.00

Cognitive-behavioural approaches to rheumatic disease: tools for clinic

Dr Emma Dures, Bristol Royal Infirmary, Bristol

09.15

The impact of symptoms: making a cognitive-behavioural formulation

Mrs Elizabeth Hale, Russells Hall Hospital, Dudley and Dr Marianne Morris, University of the West of England, Bristol

09.35

Effective goal setting in the rheumatology clinic

Prof Sarah Hewlett, Bristol Royal Infirmary, Bristol and Dr Claire Goodchild, Institute of Psychiatry, London

09.55

Activity, rest and sleep: understanding behaviour patterns

Dr Nicholas Ambler, Frenchay Hospital, Bristol and Dr Emma Dures, Bristol Royal Infirmary, Bristol

10.30 – 11.30**Poster viewing and exhibition | Tea and Coffee****Categories**

Basic Science
Cell receptor-ligand interaction, signalling, activation and apoptosis
Cytokines and inflammatory mediators
Epidemiology
Genetics
Health services research, economics and outcomes research
Miscellaneous rheumatic diseases
Muscle Disorders
Osteoarthritis: clinical features
Osteoarthritis: pathogenesis and animal models
Osteoarthritis: treatment
Scleroderma and related disorders
Sjögren's syndrome and other connective tissue disorders
Soft tissue and regional musculoskeletal disease, fibromyalgia
Spondylarthropathies (including psoriatic arthritis)
Vasculitis

Poster Tours

Epidemiology
Connective tissue disease
Spondyloarthropathy

10.30 – 11.30**NEW – Innovation theatre: Celgene**

Looking inside the cell for a new perspective on psoriatic arthritis

Prof Miles D Houslay, Chair of Pharmacological Innovation, Institute of Pharmaceutical Science, King's College London, London and Prof Oliver Fitzgerald, Newman Clinical Research Professor, School of Medicine and Medical Science, St Vincent's Hospital, Dublin, Ireland

11.30 – 13.00**Oral abstracts: Science | Hall 5**

Chairs: Prof Costantino Pitzalis, Queen Mary University of London, London and Prof Christopher Buckley, University of Birmingham, Birmingham

11.30

The role of protein kinase D signalling in the induction of matrix metalloproteinases in human articular chondrocytes

Mr Jonathan Baker, Newcastle University, Newcastle

11.45

Effects of PTPN22 R620W on neutrophil function in health and disease

Ms Rachel Bayley, University of Birmingham, Birmingham

12.00

Macrophage metabolotypes in the hypoxic inflammatory environment assessed using metabolomic profiling

Mr Martin Fitzpatrick, University of Birmingham, Birmingham

12.15

Synovial fibroblasts shape the recruitment and migration patterns of lymphocytes during resolving and persistent arthritis

Dr Helen McGettrick, University of Birmingham, Birmingham

12.30

Biological roles of C5orf30 in rheumatoid arthritis

Dr Munitta Muthana, University of Sheffield, Sheffield

12.45

Autocitrullinated porphyromonas gingivalis peptidylarginine deiminase: a novel antigen with potential for breaching immunologic tolerance in rheumatoid arthritis

Dr Anne-Marie Quirke, University of Oxford, Oxford

11.30 – 13.00**IRS Interactive clinical teaching: osteoporosis | Hall 9**

Chairs: Dr Benjamin Parker, University of Manchester, Manchester and Dr Sonia Panchal, Northampton General Hospital, Northampton

Aim:

To provide trainees with up-to-date clinical teaching on osteoporosis

Outcome 1:

To review pathophysiology of osteoporosis

Outcome 2:

To review the current evidence base for the treatment of osteoporosis

Outcome 3:

To review the management of osteoporosis outside of the current evidence base

11.30

Osteoporosis: where are we now?

Prof Bill Fraser, University of East Anglia, Norwich

12.15

Osteoporosis: what don't we know?

Prof Cyrus Cooper, University of Southampton, Southampton

11.30 – 13.00

Polymyalgia rheumatica and giant cell arteritis | Hall 1*Chair: Dr Colin Pease, Chapel Allerton Hospital, Leeds*

- Aim:** Update on diagnosis, investigations, treatment and research advances in PMR and GCA
- Outcome 1:** Apply the recent guidelines for PMR which outline an evaluative process and clues that help differentiate it from other conditions and identify overlap with inflammatory arthritis and large vessel vasculitis. They provide advice on management, goals of treatment and sources for patient education and self-management
- Outcome 2:** Learn about the EULAR ACR classification criteria which outline clinical, laboratory, and ultrasound criteria items for a scoring algorithm for PMR
- Outcome 3:** Learn about imaging studies for PMR and outcome studies to assess disease activity, quality of life and disability
- Outcome 4:** Learn about the status of disease modifying therapies and clinical trials, on-going and in setup, including the use of biological agents and other novel therapies

- 11.30 **Classification criteria and guidelines for PMR**
Prof Bhaskar Dasgupta, Southend University Hospital, Essex
- 12.00 **Polymyalgia rheumatica: the view from primary care**
Prof Christian Mallen, Keele University, Keele
- 12.20 **Imaging for large vessel vasculitis in PMR and GCA**
Prof Justin Mason, Imperial College London, London
- 12.40 **Therapy update and clinical trials for PMR and GCA**
Dr Sarah Mackie, University of Leeds, Leeds

11.30 – 13.00

Droitwich Lecture and prizes | Hall 11*Chair: Mr Robert Field, President BHPR*

- 11.30 **In defence of non-evidence based medicine**
Dr Philip Helliwell, University of Leeds, Leeds
- 12.15 **Prize ceremony**

11.30 – 13.00

Oral abstracts: Genetics | Hall 8a

Chairs: Dr Ben Rhodes, King's College London, London and Prof John Loughlin, Newcastle University, Newcastle

- 11.30 **Musculoskeletal pain is associated with BMI through shared genetic factors**
Dr Frances Williams, King's College London, London
- 11.45 **Estimating heritability of response to treatment with anti-TNF biologic agents using linear mixed models**
Dr Darren Plant, University of Manchester, Manchester
- 12.00 **Genes contributing to pain sensitivity in the normal population: an exome sequencing study**
Dr Frances Williams, King's College London, London
- 12.15 **Ankylosing spondylitis is strongly associated with variants in the CMG2 gene**
Ms Tugce Karaderi, University of Oxford, Oxford
- 12.30 **A pilot study evaluating RNA transcription profiles in idiopathic inflammatory and inclusion body myositis: a next generation sequencing approach**
Dr Philip Hamann, Royal National Hospital for Rheumatic Diseases, Bath
- 12.45 **The development of peripheral joint erosions and radiographic sacroiliitis has striking association with certain HLA alleles and haplotypes: genotype-phenotype correlation of 283 consecutive psoriatic arthritis patients**
Dr Muhammad Haroon, St Vincent's University Hospital, Dublin

11.30 – 13.00

SIG: Scleroderma | Hall 8b

Chair: Prof Christopher Denton, University College London, London

- Aim:** Update on management recommendations for SSc that are being developed and updated via EULAR, UKSSG and BSR. Implications for service provision in UK, shared care and specialist commissioning. Specific review of current best practice approaches to parenchyma
- Outcome 1:** Participants will be up-to-date on current status of evidence and expert opinion based recommendations for management of SSc
- Outcome 2:** Current best practice management of cardiac disease and lung fibrosis in SSc will be reviewed
- Outcome 3:** New methods for objective assessment of Raynaud's phenomenon and digital vascular disease will be presented
- 11.30 **Integrated management recommendations for systemic sclerosis (scleroderma)**
Prof Christopher Denton, University College London, London
- 11.45 **Current approaches to management of lung fibrosis in scleroderma**
Dr Bridget Griffiths, Freeman Hospital, Newcastle
- 12.10 **Assessment and treatment of cardiac involvement**
Dr Maya Buch, University of Leeds, Leeds
- 12.35 **Objective non-invasive assessment of digital vascular disease**
Dr Andrea Murray, University of Manchester, Manchester

11.30 – 13.00

SIG: Soft tissue rheumatism and sports medicine | Hall 10

Chair: Dr Tim Jones, The Defence Medical Rehabilitation Centre Headley Court, Surrey

Aim:

To provide a forum for discussion about the diagnosis and treatment of musculoskeletal and sports injuries and the benefits of exercise

Outcome 1:

Presentation on the recent Royal College report into the benefits of exercise in health and disease

Outcome 2:

An overview of the musculoskeletal injuries and conditions commonly found in professional dancers

Outcome 3:

A forum to discuss the future aims and organisation of the SIG in soft tissue rheumatism and sports medicine

11.30

'Exercise for life' The Royal College of Physicians 2012 report and recommendations for physical activity in health and disease

Col John Etherington, OBE FFSEM(UK) FRCP, Consultant in Rheumatology and Rehabilitation, The Defence Medical Rehabilitation Centre Headley Court, Surrey

12.00

The injury profile of the classical dancer

Dr Roger Wolman, MD FRCP FFSEM, Consultant in Rheumatology and SEM, Royal National Orthopaedic Hospital, Stanmore

12.30

Forum to discuss the aims of the SIG in musculoskeletal and sports medicine

Dr Tim Jones, The Defence Medical Rehabilitation Centre Headley Court, Surrey

13.00 – 13.30

NEW – Innovation theatre: AbbVie

Talking AS, online ankylosing spondylitis assessment for patients

Dr Raj Sengupta Royal National Hospital for Rheumatic Diseases NHS Foundation Trust, Bath

13.00 – 14.00

Exhibition | Lunch**Categories**

Basic Science
 Cell receptor-ligand interaction, signalling, activation and apoptosis
 Cytokines and inflammatory mediators
 Epidemiology
 Genetics
 Health services research, economics and outcomes research
 Miscellaneous rheumatic diseases
 Muscle Disorders
 Osteoarthritis: clinical features
 Osteoarthritis: pathogenesis and animal models
 Osteoarthritis: treatment
 Scleroderma and related disorders
 Sjögren's syndrome and other connective tissue disorders
 Soft tissue and regional musculoskeletal disease, fibromyalgia
 Spondylarthropathies (including psoriatic arthritis)
 Vasculitis

Poster Tours

Epidemiology
 Connective tissue disease
 Spondyloarthropathy

13.00 – 14.00

BHPR AGM | Hall 11

Please join your colleagues over a buffet lunch and meet BHPR Council members to hear what they have been doing on your behalf and how they plan to meet the challenges of the year ahead. This follows on from the prestigious Droitwich Lecture and the annual awarding of prizes. So do stay on to congratulate the deserving prize winners and find out how you can get more involved with BHPR, including the planned integration with BSR. Your attendance is highly valued.

13.00 – 14.00

IRS BRITs AGM | Hall 9

13.00 – 14.00

Standards, audits and guidelines working group open meeting | Hall 7**Aim:**

To increase awareness of national audits and new BSR guidelines, promoting clinician engagement

Outcome 1:

Understanding and clinician engagement in the HQIP national audit of rheumatoid and early inflammatory arthritis

Outcome 2:

Awareness of new BSR clinical guidelines to support high quality care

Outcome 3:

Awareness of how to feedback comments on draft guidelines through open consultation

This session will give an overview of activities on guideline development, guideline accreditation and national audits. There will be presentations of new guidelines and the launch of open consultation on these

BHPR AGM Networking lunch | Hall 11

Thursday 25 April | 13.00 -14.00

Please join your colleagues over a buffet lunch and meet BHPR Council members to hear what they have been doing on your behalf and how they plan to meet the challenges of the year ahead. This follows on from the prestigious Droitwich Lecture and the annual awarding of prizes. So do stay on to find out how you can get more involved with BHPR including the planned integration with BSR.

Your attendance is highly valued!

14.00 – 15.30

Advances in cartilage biology: towards a better understanding of osteoarthritis | Hall 4

Chair: Prof Ian Clark, University of East Anglia, Norwich

Aim:	To summarise recent advances in cartilage biology relevant to pathogenesis of osteoarthritis
Outcome 1:	Gain insight in novel molecular mechanisms of cartilage damage
Outcome 2:	Understand the importance of stability of the chondrocytes in osteoarthritis progression
Outcome 3:	Understand how homeostatic mechanisms can modify OA outcome and progression and how they could be harnessed for therapy
14.00	Role of injury and alarmins in osteoarthritis <i>Prof Wim Van den Berg, Radboud University Nijmegen, HC Nijmegen, The Netherlands</i>
14.20	Calcium crystals in the pathogenesis of osteoarthritis <i>Dr Jessica Bertrand, Muskuloskeletale Medizin, Munster, Germany</i>
14.40	Targeting WNT signalling in osteoarthritis <i>Dr Francesco Dell'Accio, Queen Mary, University of London, London</i>
15.05	Signals in the matrix: integrating biomechanics and cartilage homeostasis <i>Dr Tonia Vincent, Kennedy Institute of Rheumatology, London</i>

14.00 – 15.30

Career development for new consultants | Hall 9

Chairs: Dr Benjamin Parker, University of Manchester, Manchester and Dr Sonia Panchal, Northampton General Hospital, Northampton

Aim:	To provide trainees with guidance and practical advice on how they may develop their careers as new consultants
Outcome 1:	To discuss the application process for consultant posts
Outcome 2:	To highlight the opportunities available to trainees to develop additional skills pre-CCT
Outcome 3:	Delegates will have a better understanding of the broader role of a new consultant
14.00	How to survive the consultant appointments process - and succeed! <i>Dr Neil Snowden, North Manchester General Hospital, Manchester</i>
14.30	Becoming a consultant: tips from the front line <i>Dr Vinodh Devakumar, Royal Oldham Hospital, Oldham</i>
15.00	Becoming a consultant: the extended role <i>Dr Nicholas Shenker, Addenbrooke's Hospital, Cambridge</i>

14.00 – 15.30

Commissioning for rheumatology in a cold climate | Hall 5*Chair: Dr Chris Deighton, Derby Hospital Foundation Trust, Derby***Aim:**

The NHS reforms for commissioning have been implemented on 1 April 2013. Discuss and identify opportunities and threats for clinical and patient leadership in commissioning services such as rheumatology and how these can shape commissioning in the future plus key practical activities

Outcome 1:

What the key issues are that need to be addressed

Outcome 2:

Identify opportunities for improving patients outcomes and values

Outcome 3:

How can the clinical and patient voice most effectively influence policy and commissioners

Outcome 4:

Identify practical improvements and innovations

14.00

The patient and clinical voice: may the force be with you

Mrs Ailsa Bosworth, Chief Executive, National Rheumatoid Arthritis Society, Berkshire

14.10

Developing the conditions for commissioning patient pathways that would deliver better value

Prof Paul Corrigan, Director of Strategy and Commissioning of the NHS London Strategic Health Authority, London

14.25

Commissioning clinical services in a cold climate

Mrs Laura Guest, Chief Executive, British Society for Rheumatology, London

14.40

Better commissioning for service outcomes practical development

Mr Philip Ainsworth, Director of Operations, British Society for Rheumatology, London

14.55

Interactive question and answer session

Dr Chris Deighton, Derby Hospitals Foundation Trust, Derby

14.00 – 15.30

BHPR: The importance of health literacy in musculoskeletal disease | Hall 8a

Chairs: Prof David Scott, Norfolk and Norwich University Hospitals, Norwich and Ms Cathy Ball, Kennedy Institute of Rheumatology, University of Oxford, Oxford

Aim:

To provide an overview of the underpinning theory, evidence of effectiveness and strategies to enhance health literacy in patients with musculoskeletal disease

Outcome 1:

Attendees will be able to identify some of the background theories and evidence that contribute to the health literacy field

Outcome 2:

Attendees will have an awareness of the issues contributing to enhancing health literacy and some communication techniques to support these

Outcome 3:

Attendees will be aware of health literacy applications for their own practice

14.00

The evolving concept of health literacy and evidence from a systematic review of accessibility of arthritis patient education

Dr Wendy Lowe, University of Southampton, Southampton and Dr Jo Adams, University of Southampton, Southampton

14.30

The importance of health literacy in doctor patient communication

Dr Joanne Protheroe, Keele University, Keele

14.50

The importance of health literacy in patient engagement in marginalised groups

Prof Ade Adebajo, University of Sheffield, Sheffield and Ms Sandra Robinson, North Tyneside Hospital, Tyne and Wear

14.00 – 15.30

Oral abstracts: Spondyloarthritis | Hall 7

Dr Raj Sengupta, Royal National Hospital for Rheumatic Disease, Bath and Dr Andrew Keat, Northwick Park Hospital, Harrow

- 14.00 **Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results of a phase 3, randomized, controlled trial**
Prof Ade Adebajo, University of Sheffield, Sheffield
- 14.15 **Sustained efficacy of adalimumab in patients with non-radiographic axial spondyloarthritis with positive MRI of the sacroiliac joints or spine or elevated C-reactive protein at baseline**
Dr Aileen Pangan, AbbVie, Illinois, Chicago
- 14.30 **Spinal inflammation in the absence of SI joint inflammation on MRI in patients with active non-radiographic axial spondyloarthritis**
Dr Aileen Pangan, AbbVie, Illinois, Chicago
- 14.45 **Disease burden is comparable in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis**
Dr Iain Sainsbury, AbbVie, Maidenhead
- 15.00 **Effectiveness of sequential biologic use in psoriatic arthritis: results of a large retrospective survey**
Dr Meghna Jani, University of Manchester, Manchester
- 15.15 **A proposed algorithm and its performance evaluation for the best referral by ophthalmologists of acute anterior uveitis patients with possible underlying spondyloarthropathy**
Dr Muhammad Haroon, St Vincent's University Hospital, Dublin

14.00 – 15.30

SIG: Myositis | Executive Room 2

Chairs: Dr Hector Chinoy, Salford Royal NHS Foundation Trust, Salford and Dr Patrick Gordon, King's College Hospital, London

- Aim:** To provide an update on current issues in myositis and upcoming research/clinical activities
- Outcome 1:** To discuss the latest tools to be used in the diagnosis and differential diagnosis of myositis
- Outcome 2:** To discuss current paradigms in the treatment of inflammatory myositis
- Outcome 3:** To gain an understanding of the extramuscular manifestations in myositis
- 14.00 **Development of standards of treatment for adults with myositis and different phenotypes, STAMP**
Dr Sarah Tansley, Royal National Hospital for Rheumatic Disease NHS Foundation Trust, Bath
- 14.20 **Summary from the Cochrane review for treatment of myositis**
Dr Patrick Gordon, King's College Hospital, London
- 14.40 **Development of new classification criteria in myositis: the international myositis classification criteria project, IMCCP**
Dr Hector Chinoy, Salford Royal NHS Foundation Trust, Salford and Prof Robert Cooper, Salford Royal NHS Foundation Trust, Salford
- 15.05 **Challenging myositis patients: case vignettes**
Dr Harsha Gunawardena, North Bristol NHS Trust, Bristol

14.00 – 15.30

SIG: Rheumatoid arthritis | Hall 8b

Chair: Mrs Janet Cushnaghan, Southampton General Hospital, Southampton

Aim:

To provide delegates with topics of interest in the field of rheumatoid arthritis

Outcome 1:

Delegates will increase their knowledge of the early symptoms of rheumatoid arthritis

Outcome 2:

Delegates will learn about the importance of examining the feet in rheumatoid arthritis

Outcome 3:

Delegates will be able to participate in discussion around the topics presented

14.00

Understanding the early symptoms of RA

Dr Rebecca Stack, City Hospital, Birmingham

14.45

Joint inequalities: should the foot be included in routine disease assessment?

Dr Lindsey Hooper, Southampton General Hospital, Southampton

14.00 – 15.30

BHPR: The use of ultrasound for nurses and allied health professionals | Hall 10

Chairs: Dr Richard Wakefield, University of Leeds, Leeds and Dr Deborah Turner, Glasgow Caledonian University, Glasgow

Aim:

To provide nurses and allied health professionals (AHPs) with an overview of the role and clinical benefits of musculoskeletal ultrasound in rheumatology practice

Outcome 1:

Delegates will be able to identify training routes and opportunities to undertake ultrasound training

Outcome 2:

Delegates will be able to identify the benefits of using ultrasound in clinical practice and research to enhance their diagnostic skills

Outcome 3:

Delegates have a better understanding of the treatment opportunities identified using ultrasound

14.00

Training routes for nurses and AHPs in musculoskeletal ultrasound: practical considerations

Dr Catherine Bowen, University of Southampton, Southampton

14.20

The use of ultrasound to support research

Mrs Heidi Siddle, University of Leeds, Leeds

14.40

The use of ultrasonography in a physiotherapy led 'one stop' hand clinic

Mrs Mhairi Brandon, Glasgow Royal Infirmary, Glasgow

15.05

Ultrasound guided injections in rheumatology practice

Mrs Alison Hall, Cannock Chase Hospital, Cannock

16.00 – 17.30

SIG: Genetics | Executive Room 1*Chair: Prof Anne Barton, University of Manchester, Manchester*

Aim: To understand whether the investment in genetic studies has been worthwhile and what the next steps are to translation to clinical benefit

Outcome 1: The audience will learn how findings from genetic studies in osteoporosis, osteoarthritis and rheumatoid arthritis have advanced the understanding of the aetiology of those conditions

Outcome 2: Attendees will appreciate what the next steps are in investigating the loci identified

Outcome 3: The audience will understand how these findings could impact on clinical practice

16.00 **Lessons from genetic fine mapping studies of rheumatoid arthritis**

Dr Stephen Eyre, University of Manchester, Manchester

16.30 **Lessons from GWAS of osteoarthritis: where do we go from here?**

Prof John Loughlin, Newcastle University, Newcastle

16.55 **What have genetic studies of osteoporosis taught us and how can we translate this to the clinic**

Prof Stuart Ralston, University of Edinburgh, Edinburgh

16.00 – 17.30

SIG: Osteoarthritis | Hall 9*Chair: Dr Fraser Birrell, Newcastle University, Newcastle*

Aim: To share progress on OA related projects

Outcome 1: Know about the Arthritis Research UK INBANK project, OA clinical studies group progress, OA trials bank, NICE fellowship and Landmark papers book

Outcome 2: Understand potential benefits from these

Outcome 3: Network with other researchers and discuss research ideas

16.00 **Welcome and Introduction**

Dr Fraser Birrell, Newcastle University, Newcastle

16.05 **'Landmark papers' in Osteoarthritis**

Dr Fraser Birrell, Newcastle University, Newcastle

16.25 **Osteoarthritis trials bank update and NICE fellowship**

Dr Krysia Dziedzic, Keele University, Keele

16.45 **INBANK**

Prof George Peat, Keele University, Keele

17.05 **Arthritis Research UK Update:**

- Packages of care
- Experimental Medicine
- Stratified Medicine

Prof Philip Conaghan, University of Leeds, Leeds

16.00 – 17.30

SIG: RA Outcomes | Hall 8a*Chair: Dr Adam Young, West Hertfordshire Hospitals NHS Trust, St Albans*

- Aim:** To explain and explore several recent initiatives in the presentation and management of early adult inflammatory arthritis (AIA)
- Outcome 1:** Understanding the need for and likely format and impact of the INBANK hub for AIA
- Outcome 2:** How the INBANK AIA hub relates to other important recent and related initiatives like BSR audit and the MRC/ABPI projects, and the NICE assessment programme for biological therapies
- Outcome 3:** The impact of these initiatives on both academic and non-academic rheumatology departments in the UK
- 16.00 **Introduction to Early Adult Inflammatory Arthritis (AIA). How you can be involved in several new and exciting national initiatives**
Dr Adam Young, West Hertfordshire Hospitals NHS Trust, St Albans
- 16.10 **The ARUK INBANK AIA Hub project: clinical and academic involvement**
Prof Ann Morgan, St James' University Hospital, Leeds
- 16.30 **HQIP and BSR audit of RA**
Dr Ian Rowe, Worcestershire Acute Hospitals NHS Trust, Worcester
- 16.50 **The MRC Patient Stratification Initiative and Early AIA**
Prof Costantino Pitzalis, Queen Mary University of London, London
- 17.10 **BSR NICE negotiations and biologic agents**
Dr Chris Deighton, Derby Hospitals NHS Foundation Trust, Derby
- 17.20 **Open discussion**

16.00 – 17.30

SIG: Vasculitis | Hall 8b*Chair: Prof Raashid Luqmani, University of Oxford, Oxford*

- Aim:** To improve awareness of different forms of vasculitis, to update attendees on the current studies in progress to increase our understanding of the vasculitides, including diagnostic strategies, treatment and outcome
- Outcome 1:** To learn more about IgG4 related disease and how it is linked to vasculitis
- Outcome 2:** To understand what progress has been made in ongoing and new initiatives in clinical studies and trials in vasculitis
- Outcome 3:** To know what role attendees could play in current and future studies in vasculitis
- 16.00 **IgG4 related disease**
Dr Emma Culver, University of Oxford, Oxford
- 16.20 **Developing patient-reported outcome measures in vasculitis**
Dr Joanna Robson, University of Oxford, Oxford
- 16.40 **What is new in our understanding of the genetics and epidemiology of primary systemic vasculitis?**
Prof Raashid Luqmani, University of Oxford, Oxford
- 17.05 **Update on current vasculitis studies in diagnosis and assessment of vasculitis in adults and children. Brief update on European and other international studies in vasculitis**
Prof Raashid Luqmani, University of Oxford, Oxford

16.00 – 17.30

SIG: Interstitial lung disease | Hall 7*Chair: Dr Clive Kelly, Queen Elizabeth Hospital, Gateshead***Aim:**

To share with members the results of the first multi-centre UK study of the outcome of ILD in RA in the biologics era, and develop mechanisms for extending this work into prospective studies. To explore the links between both acute and chronic lung infection in patients with RA and understand the implications for clinical practice

Outcome 1:

To inform everyone of the changing natural history of RA-ILD as seen across the UK through a cohort of over 250 patients drawn from six different centres and to discuss the reasons for the improvement - and the implications for therapy

Outcome 2:

To present results of a major collaborative project exploring the pivotal role of anti-CCP antibody in the development of bronchiectasis in patients both with and without RA - and the implications for future treatment paradigms

Outcome 3:

To review the data on the contribution of acute pulmonary infection to the morbidity and mortality associated with RA, and discuss its implications for our patients. Death from pulmonary disease in its many forms has now overtaken vascular disease as the number one cause of mortality in RA in the UK!

16.00

Welcome and introduction

16.05

Development of a screening protocol for interstitial lung disease in rheumatoid arthritis*Dr Mohamed Nisar, Burton Hospitals NHS Foundation Trust, Burton-on-Trent*

16.25

UK database on RA-ILD: 25 years of data on predictors, imaging, therapeutics and survival*Dr Clive Kelly, Queen Elizabeth Hospital, Gateshead*

16.45

Interstitial lung disease in rheumatoid arthritis: a chest physician's perspective*Dr Felix Woodhead, University Hospital, Coventry*

17.05

Bronchiectasis in rheumatoid arthritis: clinical and immunological features*Dr Elizabeth Pery, Arthritis Research UK research fellow, Royal Cornwall Hospital, Truro*

17.25

Group discussion on further priorities for research and education**17.30****Meeting close**

RA CLINICAL

09.00-10.30

037 LONG-TERM OUTCOMES OF EARLY RA PATIENTS INITIATED WITH ADALIMUMAB PLUS METHOTREXATE COMPARED WITH METHOTREXATE ALONE FOLLOWING A TARGETED TREATMENT APPROACH

Roy Fleischmann¹, Ronald F. van Vollenhoven², Josef Smolen³, Paul Emery⁴, Stefan Florentinus⁵, Suchitrita Rathmann⁶, Hartmut Kupper⁷, Arthur Kavanaugh⁸

¹Rheumatology, University of Texas Southwestern, Dallas, TX, USA; ²Rheumatology, The Karolinska Institute, Stockholm, Sweden; ³Institute of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria; ⁴Musculoskeletal Disease, Leeds Teaching Hospital, Leeds, United Kingdom; ⁵Rheumatology Medical Affairs, AbbVie, Rungis, France; ⁶Data and Statistical Sciences, AbbVie, North Chicago, IL, USA; ⁷Immunology Development, AbbVie GmbH and Co. KG, Ludwigshafen, Germany; ⁸Rheumatology, Allergy and Immunology, University of California San Diego, La Jolla, CA, USA

038 24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS

Peter Taylor¹, Mark Genovese², Edward C. Keystone³, Edit Drescher⁴, Pierre-Yves Berclaz⁵, Chin Lee⁵, Rosalind Fidelus-Gort⁶, Douglas Schlichting⁵, Scott Beattie⁵, Monica Luchi⁶, William Macias⁵

¹Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom; ²School of Medicine, Stanford University, Palo Alto, CA, USA; ³School of Medicine, University of Toronto, Toronto, ON, Canada; ⁴Department of Rheumatology and Physical Rehabilitation, Veszprém Csolnoky Ferenc County Hospital, Veszprém, Hungary; ⁵Lilly Research Labs, Eli Lilly and Co., Indianapolis, IN, USA; ⁶Incyte Corporation, Wilmington, DE, USA

039 TOCILIZUMAB MONOTHERAPY COMPARED WITH ADALIMUMAB MONOTHERAPY IN RA: RESULTS OF A 24-WEEK STUDY

Arthur Kavanaugh¹, Paul Emery², Ronald F. van Vollenhoven³, Ara H. Dikranian⁴, Rieke Alten⁵, Micki Klearman⁶, David Musselman⁶, Sunil Agarwal⁶, Jennifer Green⁷, Cem Gabay⁸

¹Rheumatology, UCSD School of Medicine, La Jolla, CA, USA; ²Rheumatology, University of Leeds, Leeds, United Kingdom; ³Rheumatology, Karolinska Institute, Stockholm, Sweden; ⁴Rheumatology, San Diego Arthritis Medical Clinic, San Diego, CA, USA; ⁵Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany; ⁶Medical, Genentech Inc., San Francisco, CA, USA; ⁷Medical, Roche Products Ltd, Welwyn Garden City, United Kingdom; ⁸Rheumatology, Geneva University Hospitals, Geneva, Switzerland

040 HEAD-TO-HEAD COMPARISON OF SUBCUTANEOUS ABATACEPT VERSUS ADALIMUMAB IN THE TREATMENT OF RHEUMATOID ARTHRITIS: KEY EFFICACY AND SAFETY RESULTS FROM THE AMPLE TRIAL

Michael E. Weinblatt¹, Michael H. Schiff², Roy Fleischmann³, Robert Valente⁴, Desiree van der Heijde⁵, Gustavo Citera⁶, Cathy Zhao⁷, Michael A. Maldonado⁸

¹Rheumatology and Immunology, Brigham and Women's Hospital, Boston, MA, USA; ²Rheumatology Division, University of Colorado, Denver, CO, USA; ³Department of Internal Medicine, University of Texas Southwestern Medical Centre, Dallas, TX, USA; ⁴Rheumatology, Arthritis Centre of Nebraska, Lincoln, NE, USA; ⁵Department of Rheumatology, Leiden University Medical Centre, Leiden, Netherlands; ⁶Section of Rheumatology, Instituto de Rehabilitación Psicosfísica, Buenos Aires, Argentina; ⁷Global Biometric Sciences, Bristol-Myers Squibb, Princeton, NJ, USA; ⁸Medical Affairs, Bristol-Myers Squibb, Princeton, NJ, USA

041 WHAT HAPPENS TO ACPA POSITIVE PATIENTS WITHOUT CLINICAL SYNOVITIS?

Chadi Rakieh¹, Jacqueline L. Nam¹, Laura Hunt¹, Edith Villeneuve¹, Lesley-Anne Bissell¹, Sudipto Das¹, Philip Conaghan¹, Dennis McGonagle¹, Richard J. Wakefield¹, Paul Emery¹

¹Division of Rheumatic and Musculoskeletal Disease, LIMM, University of Leeds, Leeds, United Kingdom

042 INTERFERON GENE EXPRESSION SIGNATURE IN NEUTROPHILS FROM RA PATIENTS PRE AND POST ANTI-TNF THERAPY

Helen L. Wright¹, Huw B. Thomas¹, Robert Moots², Steven W. Edwards¹

¹Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom; ²Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom

GENETICS

11.30 - 13.00

043 A PILOT STUDY EVALUATING RNA TRANSCRIPTION PROFILES IN IDIOPATHIC INFLAMMATORY AND INCLUSION BODY MYOSITIS: A NEXT GENERATION SEQUENCING APPROACH

Phillip Hamann^{1,2}, James Heward², Neil McHugh^{1,2}, Mark A. Lindsay²

¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom; ²Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom

044 THE DEVELOPMENT OF PERIPHERAL JOINT EROSIONS AND RADIOGRAPHIC SACROILIITIS HAS STRIKING ASSOCIATION WITH CERTAIN HLA ALLELES AND HAPLOTYPES: GENOTYPE-PHENOTYPE CORRELATION OF 283 CONSECUTIVE PSORIATIC ARTHRITIS PATIENTS

Muhammad Haroon¹, Jon T. Giles², Robert Winchester³, Oliver FitzGerald¹

¹Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland; ²Rheumatology, Columbia University, New York, NY, USA; ³Rheumatology, Columbia University Medical Centre, New York, NY, USA

045 ANKYLOSING SPONDYLITIS IS STRONGLY ASSOCIATED WITH VARIANTS IN THE CMG2 GENE

Tugce Karaderi¹, Carla J. Cohen¹, Sarah Keidel¹, Louise H. Appleton¹, Gary J. Macfarlane², Stefan Siebert³, David Evans⁴, B Paul Wordsworth^{1,5}

¹Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom; ²Epidemiology Group, Institute of Applied Health Sciences, School of Medicine and Dentistry, University of Aberdeen, Aberdeen, United Kingdom; ³Rheumatology Department, Swansea University, Swansea, United Kingdom; ⁴MRC Centre for Causal Analyses in Translational Epidemiology, School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom; ⁵NIHR Comprehensive Biomedical Research Centre and Musculoskeletal Biomedical Research Unit, Nuffield Orthopaedic Centre, University of Oxford, Oxford, United Kingdom

046 ESTIMATING HERITABILITY OF RESPONSE TO TREATMENT WITH ANTI-TNF BIOLOGIC AGENTS USING LINEAR MIXED MODELS

Darren Plant¹, John Bowes¹, Gisela Orozco¹, Ann W. Morgan², Anthony G. Wilson³, John Isaacs⁴, Anne Barton^{1,5}

¹Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom; ²NIHR - Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom; ³Academic Unit of Rheumatology, Department of Infection and Immunity, University of Sheffield, Sheffield, United Kingdom; ⁴Musculoskeletal Research Group, University of Newcastle and Newcastle Hospitals NHS Foundation Trust, Newcastle, United Kingdom; ⁵Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate, United Kingdom

047 MUSCULOSKELETAL PAIN IS ASSOCIATED WITH BMI THROUGH SHARED GENETIC FACTORS

Frances M. Williams¹, Gregory Livshits², Tim Spector¹, Alexander MacGregor³

¹Twin Research and Genetic Epidemiology, King's College London, London, United Kingdom; ²Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; ³Norwich Medical School, University of East Anglia, Norwich, United Kingdom

048 GENES CONTRIBUTING TO PAIN SENSITIVITY IN THE NORMAL POPULATION: AN EXOME SEQUENCING STUDY

Frances M. Williams¹, Serena Scollen², Dandan Cao³, Yasin Memari⁴, Craig L. Hyde⁵, Baohong Zhang⁵, Benjamin Sidders², Daniel Ziemek⁵, Yujian Shi³, Juliette Harris¹, Ian Harrow², Brian Dougherty⁵, Anders Malarstig², Robert McEwen², Joel L. Stephens⁵, Ketan Patel⁵, So-Youn Shin⁴, Gabriela Surdulescu¹, Wen He⁵, Xin Jin³, Stephen B. McMahon⁶, Nicole Soranzo⁴, Sally John⁵, Jun Wang³, Tim D. Spector¹

¹Twin Research and Genetic Epidemiology, King's College London, London, United Kingdom; ²Neusentis, Pfizer Ltd, Cambridge, United Kingdom; ³BGI-Shenzhen, Beijing Genomics Institute, Shenzhen, China; ⁴Wellcome Trust Sanger Institute, Hinxton, United Kingdom; ⁵Pfizer Research Laboratories, Pfizer Inc, Groton, CT, USA; ⁶Wolfson CARD, King's College London, London, United Kingdom

SCIENCE

11.30 - 13.00



Young investigator award winner

049 THE ROLE OF PROTEIN KINASE D SIGNALLING IN THE INDUCTION OF MATRIX METALLOPROTEINASES IN HUMAN ARTICULAR CHONDROCYTES

Jonathan Baker¹, Gary J. Litherland¹, Andrew D. Rowan¹

¹Musculoskeletal Research Group, University of Newcastle, Newcastle, United Kingdom

050 EFFECTS OF PTPN22 R620W ON NEUTROPHIL FUNCTION IN HEALTH AND DISEASE

Kerry A. Kite¹, Rachel Bayley¹, Peiming Yang¹, Jacqueline P. Smith², Julie Williams³, Lorraine Harper³, George D. Kitas², Christopher Buckley¹, Stephen P. Young¹

¹Rheumatology Research Group, University of Birmingham, Birmingham, United Kingdom; ²Department of Rheumatology, Russell's Hall Hospital, Dudley, United Kingdom; ³Department of Renal Immunology, University of Birmingham, Birmingham, United Kingdom



Young investigator award winner

051 MACROPHAGE METABOTYPES IN THE HYPOXIC INFLAMMATORY ENVIRONMENT ASSESSED USING METABOLOMIC PROFILING

Martin A. Fitzpatrick¹, Stephen P. Young¹

¹CTIR, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom

052 SYNOVIAL FIBROBLASTS SHAPE THE RECRUITMENT AND MIGRATION PATTERNS OF LYMPHOCYTES DURING RESOLVING AND PERSISTENT ARTHRITIS

Helen M. McGettrick^{1,2}, Andrew Filer^{1,2}, Karim Raza¹, Gerard Nash³, Christopher Buckley^{1,2}

¹Rheumatoid Arthritis Centre for Excellence, University of Birmingham, Birmingham, United Kingdom; ²System Sciences for Health, University of Birmingham, Birmingham, United Kingdom; ³Centre for Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom

053 BIOLOGICAL ROLES OF C5ORF30 IN RHEUMATOID ARTHRITIS

Munitta Muthana¹, Holly Davies¹, Sachin Khetan¹, Gbadebo Adeleke¹, Sarah Hawtree¹, Simon Tazzyman², Fiona Morrow¹, Barbara Ciani³, Gerry Wilson¹

¹Infection and Immunity, University of Sheffield, Sheffield, United Kingdom; ²Oncology, University of Sheffield, Sheffield, United Kingdom; ³Chemistry, University of Sheffield, Sheffield, United Kingdom

054 AUTOCITRULLINATED PORPHYROMONAS GINGIVALIS PEPTIDYLARGININE DEIMINASE: A NOVEL ANTIGEN WITH POTENTIAL FOR BREACHING IMMUNOLOGIC TOLERANCE IN RHEUMATOID ARTHRITIS

Anne-Marie Quirke¹, Elena Lugli¹, Natalia Wegner², Peter Charles¹, Bart Hamilton³, Muslima Chowdhury¹, Jimmy Ytterberg⁴, Jan Potempa⁵, Benjamin Fisher², Geoffrey Thiele³, Ted Mikuls³, Patrick Venables¹

¹Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom; ²Kennedy Institute of Rheumatology, Imperial College London, London, United Kingdom; ³University of Nebraska Medical Centre, University of Nebraska, Omaha, NE, USA; ⁴Department of Medicine, Karolinska Institute, Stockholm, Sweden; ⁵Department of Microbiology, Jagiellonian University, Krakow, Poland

SPONDYLOARTHRTIS

14.00-15.30

055 APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS OF A PHASE III RANDOMIZED CONTROLLED TRIAL

Adewale O. Adebajo¹, Arthur Kavanaugh², Philip Mease³, Juan J. Gomez-Reino⁴, Jurgen Wollenhaupt⁵, ChiaChi Hu⁶, Randall Stevens⁶

¹Rheumatology, University of Sheffield, Sheffield, United Kingdom; ²Rheumatology, University of California San Diego, San Diego, CA, USA; ³Rheumatology, Swedish Medical Centre and University of Washington School of Medicine, Seattle, WA, USA; ⁴Rheumatology, Hospital Clinico Universitario, Santiago, Spain; ⁵Rheumatology, Schön Klinik Hamburg Eilbek, Hamburg, Germany; ⁶Research and Development, Celgene Corporation, Warren, NJ, USA

056 SUSTAINED EFFICACY OF ADALIMUMAB IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRTIS WITH POSITIVE MRI OF THE SACROILIAC JOINTS OR SPINE OR ELEVATED C-REACTIVE PROTEIN AT BASELINE

Joachim Sieper¹, Desiree van der Heijde², Maxime Dougados³, Filip Van den Bosch⁴, Philippe Goupille⁵, Suchitrita S. Rathmann⁶, Aileen L. Pangan⁷

¹Department of Medicine/Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany; ²Department of Rheumatology, Leiden University Medical Centre, Leiden, Netherlands; ³Department of Rheumatology, Hospital Cochin, Paris, France; ⁴Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; ⁵Department of Rheumatology, CHRU de Tours, Hôpital Trousseau, Tours, France; ⁶Data and Statistical Sciences, AbbVie, North Chicago, IL, USA; ⁷Immunology Development, AbbVie, North Chicago, IL, USA

057 SPINAL INFLAMMATION IN THE ABSENCE OF SI JOINT INFLAMMATION ON MRI IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRTIS

Desiree van der Heijde¹, Joachim Sieper², Walter P. Maksymowych³, Matthew A. Brown⁴, Suchitrita Rathmann⁵, Aileen L. Pangan⁶

¹Rheumatology, Leiden University Medical Centre, Leiden, Netherlands; ²Gastroenterology and Rheumatology, Charité Universitätsmedizin, Berlin, Germany; ³Medicine, University of Alberta, Edmonton, AB, Canada; ⁴Autoimmunity Program, University of Queensland Diamantina Institute, Brisbane, QLD, Australia; ⁵Data and Statistical Sciences, AbbVie, North Chicago, IL, USA; ⁶Immunology Development, AbbVie, North Chicago, IL, USA

058 DISEASE BURDEN IS COMPARABLE IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRTIS AND ANKYLOSING SPONDYLITIS

Joachim Sieper¹, Desiree van der Heijde², Dirk Elewaut³, Aileen L. Pangan⁴, Jaclyn Anderson⁴

¹Department of Medicine/Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany; ²Department of Rheumatology, Leiden University Medical Centre, Leiden, Netherlands; ³Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; ⁴Immunology Development, AbbVie, North Chicago, IL, USA



Innovation award winner

O59 A PROPOSED ALGORITHM AND ITS PERFORMANCE EVALUATION FOR THE BEST REFERRAL BY OPHTHALMOLOGISTS OF ACUTE ANTERIOR UVEITIS PATIENTS WITH POSSIBLE UNDERLYING SPONDYLOARTHROPATHY


Muhammad Haroon¹, Pathma Ramasamy², Michael O'Rourke², Conor Murphy², Oliver FitzGerald¹

¹Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland; ²Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland

O60 EFFECTIVENESS OF SEQUENTIAL BIOLOGIC USE IN PSORIATIC ARTHRITIS: RESULTS OF A LARGE RETROSPECTIVE SURVEY

Meghna Jani^{1,2}, Sarah Moore³, Hoda Mirjafari⁴, Elizabeth Macphie⁵, Hector Chinoy^{1,2}, Chan Rao⁶, Yokemei McLoughlin³, Shah Preeti

¹Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom; ²Department of Rheumatology, Salford Royal NHS Foundation Trust, Salford, United Kingdom; ³Department of Rheumatology, Trafford General Hospital, Manchester, United Kingdom; ⁴Department of Rheumatology, University Hospital of South Manchester, Manchester, United Kingdom; ⁵Department of Rheumatology, Lancashire Teaching Hospitals, Preston, United Kingdom; ⁶Department of Rheumatology, Blackpool Teaching Hospitals, Blackpool, United Kingdom



Poster viewing

Thursday 25 April 2013



Don't forget
to sign up for
poster tours!

BASIC SCIENCE

208 STEM CELL FACTOR EXPRESSION IS INCREASED IN THE SKIN OF PATIENTS WITH SYSTEMIC SCLEROSIS AND PROMOTES PROLIFERATION AND MIGRATION OF FIBROBLASTS IN VITRO

Sarah Karrar¹, Xu Shiwen¹, Joana Nikotorowicz-Buniak¹, David J. Abraham¹, Christopher Denton¹, Richard Stratton¹

¹Centre for Rheumatology, University College London, London, United Kingdom

209 FROM HEALTH TO AUTOIMMUNITY: EFFECTS OF PTPN22 R620W AND SMOKING ON CD4+ T-CELL SIGNALLING AND CYTOKINE PRODUCTION

Rachel Bayley¹, Kerry A. Kite¹, Elizabeth Clay¹, Jacqueline P. Smith², George D. Kitas², Christopher Buckley¹, Stephen P. Young¹

¹Rheumatology Research Group, The University of Birmingham, Birmingham, United Kingdom; ²Department of Rheumatology, Russell's Hall Hospital, Dudley, United Kingdom

210 ALTERED FREQUENCIES OF REGULATORY T-CELL SUBSETS IN ANKYLOSING SPONDYLITIS AND RHEUMATOID ARTHRITIS PATIENTS AND THEIR RESPONSE TO ANTI-TNF THERAPY

Lingying Ye^{1,2}, Libin Zhang¹, Jane Goodall², Hill Gaston², Hui Xu¹

¹Department of Rheumatology, Changzheng Hospital, Second Military Medical University, Shanghai, China; ²Department of Medicine, University of Cambridge, Cambridge, United Kingdom

211 ALTERATIONS IN CIRCULATING T FOLLICULAR HELPER CELLS AND T REGULATORY CELLS IN AUTOIMMUNE RHEUMATIC DISEASES TREATED WITH B-CELL DEPLETION THERAPY: RITUXIMAB

Pamela M. Lutalo^{1,2}, Yuan Zhao¹, Lee Meng Choong², Shirish Sangle², Jo Spencer¹, David D'Cruz²

¹Peter Gorer Department of Immunobiology, King's College London, London, United Kingdom; ²The Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom

212 DIRECT VISUALISATION OF HLA-B27 FORMS IN CELL LINES AND SPONDYLOARTHROPATHY TISSUES

Oliwia J. Rysnik¹, Kirsty McHugh¹, Paul Bowness¹

¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

213 DIFFERENTIAL GENERATION OF CC CHEMOKINES AT MICROVASCULAR ENDOTHELIAL CELLS OF BLOOD AND LYMPHATIC VESSELS UNDER INFLAMMATORY CONDITIONS

Lisa Rump-Goodrich¹, Derek Matthey¹, Oksana Kehoe¹, Jim Middleton^{1,2}

¹RJAH Orthopaedic Hospital, Keele University, Oswestry, United Kingdom; ²School of Medicine and Dentistry, University of Bristol, Bristol, United Kingdom

CELL RECEPTOR-LIGAND INTERACTION, SIGNALLING, ACTIVATION AND APOPTOSIS

214 HUNTING THE LIGAND FOR ORPHAN RECEPTOR GPR15/BOB WHOSE EXPRESSION IS UP-REGULATED IN RHEUMATOID ARTHRITIS PATIENTS

Alison Cartwright¹, Caroline Schmutz², Ayman Askari³, Jim Middleton^{1,4}

¹Institute of Science and Technology in Medicine, Keele University at RJAH Orthopaedic Hospital, Oswestry, United Kingdom; ²Division of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom; ³Rheumatology, RJAH Orthopaedic Hospital NHS Foundation Trust, Oswestry, United Kingdom; ⁴Faculty of Medicine and Dentistry, University of Bristol, Bristol, United Kingdom

215 ABATACEPT SENSITIVITY IS DETERMINED BY FACTORS THAT DEFINE THE STRENGTH OF T-CELL RECEPTOR SIGNALLING

David H. Gardner¹, Louisa E. Jeffery¹, Karim Raza^{1,2}, David M. Sansom¹

¹MRC Centre for Immune Regulation, University of Birmingham, Birmingham, United Kingdom; ²Department of Rheumatology, Sandwell and West Birmingham NHS trust, Birmingham, United Kingdom

216 DIMINISHED ENVIRONMENTAL OXYGEN ALTERS MEMORY T-CELL RESPONSES TO STIMULATION, WITH SEVERE HYPOXIA DEPRESSING BOTH CYTOKINE PRODUCTION AND TH2 CELL DEVELOPMENT

Elizabeth Clay¹, Rachel Bayley¹, Martin Fitzpatrick¹, Graham Wallace¹, Stephen Young¹

¹School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom

217 THE ARTHRITIS-ASSOCIATED HLA-B*27:05 FORMS MORE CELL SURFACE B27 DIMER AND FREE HEAVY CHAIN LIGANDS FOR KIR3DL2 AND LILRB2 IMMUNORECEPTORS THAN HLA*B27:09

Jacqueline Shaw¹, Hiroko Hatano¹, Alberto Cauli², Joanna L. Giles¹, Kirsty McHugh¹, Alessandro Mathieu², Paul Bowness¹, Simon Kollnberger¹

¹Botnar Research Centre, NDORMS, Oxford, United Kingdom; ²Department of Medical Sciences, University of Cagliari, Cagliari, Italy

CYTOKINES AND INFLAMMATORY MEDIATORS

218 PKR ACTIVATES THE INTEGRATED STRESS RESPONSE FOLLOWING BACTERIAL INFECTION AND INITIATES PRO-INFLAMMATORY REPROGRAMMING OF THE CELL

Steve Webster¹, Lou Ellis¹, Louise M. O'Brien¹, Tim J. Fitzmaurice¹, Hill Gaston¹, Jane Goodall¹

¹Medicine, University of Cambridge, Cambridge, United Kingdom

219 CHARACTERISATION OF ENZYMES INVOLVED IN NICOTINAMIDE ADENINE DINUCLEOTIDE BIOSYNTHESIS IN RHEUMATOID ARTHRITIS SYNOVIUM AND CYTOKINE-STIMULATED SYNOVIAL FIBROBLASTS

Abdul Nazeer Moideen^{1,2}, Laura Evans¹, Louise Osgood¹, Anwen Williams¹, Simon Jones¹, Christopher Thomas¹, Valerie O'Donnell¹, Mari Nowell¹

¹Institute of Infection and Immunity, Cardiff University, Cardiff, United Kingdom; ²Trauma and Orthopaedics, Cardiff and Vale University Health Board, Cardiff, United Kingdom

220 ACTIVATION OF THE X-BOX BINDING PROTEIN 1 AS A MEDIATOR OF INFLAMMATION IN RHEUMATOID ARTHRITIS AND EFFECTS OF PRO-INFLAMMATORY STIMULI ON REGULATION OF EXPRESSION OF MICRORNA

Lylia Ouboussad¹, Sinisa Savic¹, Laura J. Dickie¹, Janina Hintze¹, Chi H. Wong¹, Graham P. Cook², Maya Buch³, Paul Emery³, Michael F. McDermott¹

¹NIHR-Leeds Musculoskeletal Biomedical Research Unit LIMM, University of Leeds, Leeds, United Kingdom; ²Section of Oncology and Clinical Research LIMM, University of Leeds, Leeds, United Kingdom; ³Chapel Allerton Hospital, University of Leeds, Leeds, United Kingdom

EPIDEMIOLOGY

221 PREVALENCE OF JOINT REPLACEMENT IS INCREASED IN HIGH BONE MASS

Sarah A. Hardcastle¹, Celia L. Gregson^{1,2}, Kevin Deere¹, George Davey Smith^{3,4}, Paul Dieppe^{1,5}, Jonathan H. Tobias¹

¹Musculoskeletal Research Unit, University of Bristol, Bristol, United Kingdom; ²MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom; ³MRC Centre for Causal Analyses in Translational Epidemiology, University of Bristol, Bristol, United Kingdom; ⁴School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom; ⁵Institute of Health Services Research, University of Exeter Medical School, Exeter, United Kingdom



222 HOW IMPORTANT IS OCCUPATIONAL ACTIVITY IN DETERMINATION OF TOTAL FEMUR BONE MINERAL DENSITY? FINDINGS FROM THE HERTFORDSHIRE COHORT STUDY



Elaine Dennison¹, Mark Edwards¹, James Bennett¹, David Coggon¹, Keith Palmer¹, Cyrus Cooper^{1,2}

¹MRC Lifecourse Epidemiology Unit, Southampton University, Southampton, United Kingdom; ²Institute of Musculoskeletal Science, University of Oxford, Oxford, United Kingdom

223 PEOPLE LIVING IN DEPRIVED AREAS DISPLAY GREATER DISABILITY AFTER 2 YEARS OF RHEUMATOID ARTHRITIS: THE ERAN COHORT.



Dan McWilliams¹, Adam Young², Patrick D. Kiely³, David Walsh^{1,4}

¹Arthritis Research UK Pain Centre, University of Nottingham, Nottingham, United Kingdom; ²Rheumatology, West Hertfordshire Hospitals NHS Trust, St Albans, United Kingdom; ³Rheumatology, St George's Healthcare NHS Trust, London, United Kingdom; ⁴Rheumatology, Sherwood Forest Hospitals NHS Foundation Trust, Sutton-in-Ashfield, United Kingdom

224 IDENTIFYING SCOLIOSIS IN POPULATION-BASED COHORTS: DEVELOPMENT AND VALIDATION OF A NOVEL METHOD BASED ON TOTAL BODY DUAL ENERGY X-RAY ABSORPTIOMETRY SCANS



Hilary J. Taylor¹, Ian Harding², John Hutchinson², Ian Nelson², Ashley Blom^{1,2}, Jon Tobias¹, Emma Clark¹

¹Academic Rheumatology, Avon Orthopaedic Centre, Bristol, United Kingdom; ²Orthopaedics, North Bristol NHS Trust, Bristol, United Kingdom

225 T SCORE THRESHOLDS AS PREDICTORS OF FRACTURES IN MEN



Joshua Parker¹, Marwan Bukhari¹

¹Rheumatology Department, Royal Lancaster Infirmary, Lancaster, United Kingdom

226 THE CONTRIBUTION OF THE PATIENT-REPORTED COMPONENTS OF DAS28 TO PREDICTION OF RADIOGRAPHIC PROGRESSION IN THE ERAN COHORT



Dan McWilliams¹, Keeranur Jayakumar², Adam Young³, Patrick Kiely⁴, David Walsh^{1,5}

¹Arthritis Research UK Pain Centre, University of Nottingham, Nottingham, United Kingdom; ²Rheumatology, Heart of England NHS Foundation Trust, Birmingham, United Kingdom; ³Rheumatology, West Hertfordshire Hospitals NHS Trust, St Albans, United Kingdom; ⁴Rheumatology, St George's Healthcare NHS Trust, London, United Kingdom; ⁵Rheumatology, Sherwood Forest Hospitals NHS Foundation Trust, Sutton-in-Ashfield, United Kingdom

227 HAS THE BASELINE SEVERITY OF INFLAMMATORY POLYARTHRITIS DIMINISHED OVER TIME?



Janet Diffin¹, Mark Lunt¹, Tarnya Marshall², Jackie Chipping³, Deborah Symmons¹, Suzanne Verstappen¹

¹Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom; ²Department of Rheumatology, Norfolk and Norwich University Hospital, Norwich, United Kingdom; ³Norfolk Arthritis Register, School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, United Kingdom

228 SMALLER BONES AT AGE 9 PREDICTS SCOLIOSIS AT AGE 15: RESULTS FROM A POPULATION-BASED BIRTH COHORT



Hilary J. Taylor¹, Ian Harding², John Hutchinson², Ian Nelson², Jon Tobias¹, Emma Clark¹

¹Academic Rheumatology, Avon Orthopaedic Centre, Bristol, United Kingdom; ²Orthopaedics, North Bristol NHS Trust, Bristol, United Kingdom

GENETICS

229 USING ENCODE DATA TO IDENTIFY POTENTIAL FUNCTIONAL GENETIC VARIANTS AT THE 5Q31 PSORIATIC ARTHRITIS SUSCEPTIBILITY LOCUS

James Bluett¹, John Bowes¹, Pauline Ho^{1,2}, Neil McHugh³, David Buden⁴, Oliver Fitzgerald⁵, Anne Barton¹

¹Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom; ²The Kellgren Centre for Rheumatology, Central Manchester Foundation Trust, Manchester, United Kingdom; ³Royal National Hospital for Rheumatic Diseases and Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom; ⁴Department of Dermatology, Southern General Hospital, Glasgow and Royal Hospital for Sick Children, Glasgow, United Kingdom; ⁵Department of Rheumatology, St Vincent's University Hospital, UCD School of Medicine and Medical Sciences and Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland

230 GENOME-WIDE DNA METHYLATION PROFILING IN T CELLS FROM PATIENTS WITH RHEUMATOID ARTHRITIS

John R. Glossop^{1,2}, Nicola B. Nixon², Richard D. Emes³, Peter T. Dawes², William E. Farrell¹, Derek L. Matthey^{1,2}

¹Institute for Science and Technology in Medicine, Keele University, Keele, United Kingdom; ²Rheumatology, Haywood Rheumatology Centre, Haywood Hospital, Stoke-on-Trent, United Kingdom; ³School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington Campus, United Kingdom

231 PREDICTING THE RISK OF RHEUMATOID ARTHRITIS AND ITS AGE OF ONSET: MODELLING GENETIC RISK VARIANTS WITH SMOKING

Ian C. Scott^{1,2}, Sophia Steer³, Seth Seegobin¹, Anne M. Hinks⁴, Stephen Eyre⁴, Ann Morgan⁵, Anthony G. Wilson⁶, Lynne Hocking⁷, Paul Wordsworth⁸, Anne Barton⁴, Jane Worthington⁴, Andrew Cope², Cathryn M. Lewis¹

¹Medical and Molecular Genetics, King's College London, London, United Kingdom; ²Academic Department of Rheumatology, King's College London, London, United Kingdom; ³Department of Rheumatology, King's College Hospital, London, United Kingdom; ⁴Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom; ⁵Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, St. James's University Hospital, Leeds, United Kingdom; ⁶Academic Unit of Rheumatology, The University of Sheffield Medical School, Sheffield, United Kingdom; ⁷Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom; ⁸Nuffield Department of Orthopaedics, University of Oxford, Oxford, United Kingdom

232 JNK-1 SHOWS AN ASSOCIATION WITH ACA AND ARA POSITIVE SSC PATIENTS

Sandra Guerra¹, Bahja A. Ahmed¹, Christopher Denton¹, David Abraham¹, Carmen Fonseca¹

¹Inflammation, University College London, London, United Kingdom

233 FINE MAPPING THE FCGR2A ASSOCIATION WITH SUSCEPTIBILITY TO RHEUMATOID ARTHRITIS

James Robinson¹, John Taylor¹, Lubna Haroon Rashid¹, Edward Flynn², Stephen Eyre², Jane Worthington², Anne Barton², John Isaacs³, John Bowes², Anthony G. Wilson⁴, Jennifer H. Barrett¹, Ann Morgan¹

¹Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom; ²Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom; ³Institute of Cellular Medicine, University of Newcastle, Newcastle, United Kingdom; ⁴Department of Infection and Immunity, University of Sheffield, Sheffield, United Kingdom

**HEALTH SERVICES RESEARCH, ECONOMICS
AND OUTCOMES RESEARCH**

234 OUTCOME DATA FROM A STANDARDISED CARE PATHWAY FOR NEWLY DIAGNOSED RHEUMATOID ARTHRITIS

Belinda Kingston¹, Mohamed Ahmed¹, John R. Kirwan¹, Robert Marshall¹

¹Rheumatology Department, Bristol Royal Infirmary, Bristol, United Kingdom

235 DOES AN ACUTE HOT JOINT SERVICE REDUCE ADMISSION AND LENGTH OF STAY?

Kate Chapman¹, Robert Pearson¹, Carol Heycock¹, Clive Kelly¹, Martin Rynne¹, Vadivelu Saravanan¹, Jennifer Hamilton¹

¹Rheumatology, Queen Elizabeth Hospital, Gateshead, United Kingdom

236 AN AUDIT OF MISSED RHEUMATOLOGY OUTPATIENT APPOINTMENTS

Aamir Saeed¹, Robert Coughlan¹, John J Carey¹

¹Rheumatology, University College Hospitals, Galway, Ireland

237 ARE WE MANAGING THE ACUTE HOT SWOLLEN JOINT ACCORDING TO THE NATIONAL GUIDELINE 5 YEARS ON?

Ziad Farah^{1,2}, Wendy Matthews²

¹Medicine, London Deanery, London, United Kingdom;
²Accident and Emergency, Imperial College Healthcare NHS Trust, London, United Kingdom

238 WASTE NOT, WANT NOT: IS ANTI-TNF WASTAGE PREVENTABLE?

Carolyn Bell¹, Sharon Petford¹, Lisa-Marie Tibbetts¹, Karen M.J. Douglas¹

¹Department of Rheumatology, Dudley Group of Hospitals NHS Trust, West Midlands, United Kingdom

239 SIGNIFICANT REDUCTION IN BIOLOGIC PRESCRIBING COSTS WHILST MAINTAINING REMISSION IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS

Wendy Holden¹

¹Rheumatology, Hampshire Hospitals NHS Foundation Trust, Basingstoke, United Kingdom

240 VARIATION IN CASE MIX AND SERVICE PROVISION ACROSS WESSEX RHEUMATOLOGY UNITS: AN UPDATE

Joanna Ledingham¹, Margaret Fletcher¹

¹Rheumatology Department, Queen Alexandra Hospital, Portsmouth, United Kingdom

241 GROUP DMARD COUNSELLING CLINICS: SAVING TIME WHILST MAINTAINING HIGH LEVELS OF PATIENT SATISFACTION

Rachel Winfield¹, Zoe Price¹, Kirsten Mackay¹, Chris Dixon¹

¹Rheumatology Department, South Devon Healthcare NHS Foundation Trust, Torquay, United Kingdom

242 COST-EFFECTIVENESS OF JOINT PROTECTION AND HAND EXERCISE FOR HAND OSTEOARTHRITIS

Raymond Oppong^{1,2}, Sue Jowett^{1,2}, Elaine Nicholls¹, David Whitehurst^{1,3}, Sue Hill¹, Alison Hammond⁴, Elaine Hay¹, Krysia Dziedzic¹

¹Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom; ²Health Economics Unit, School of Health and Population Sciences, University of Birmingham, Birmingham, United Kingdom; ³Faculty of Health Science, Simon Fraser University, Burnaby, Canada; ⁴Centre for Health, Sport and Rehabilitation Research, Salford University, Greater Manchester, United Kingdom

243 BIOLOGIC THERAPIES FOR RHEUMATOID ARTHRITIS: ELIGIBILITY CRITERIA IN THE UK

Carina Righetti¹, Maximilian Lebmeier¹, Subash Srinivasan²

¹Health Economics and Outcomes Research, Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, United Kingdom; ²UK Medical Affairs, Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, United Kingdom

- 244 A BRIEF EXERCISE AND SELF-MANAGEMENT PROGRAMME IMPROVES UPPER LIMB DISABILITY IN PEOPLE WITH EARLY RHEUMATOID ARTHRITIS**
Victoria L. Manning¹, Michael Hurley², David L. Scott¹, Ernest Choy³, Lindsay Bearn¹

¹School of Medicine, King's College London, London, United Kingdom; ²School of Rehabilitation Sciences, St George's University of London and Kingston University, London, United Kingdom; ³Cardiff Institute of Infection and Immunity, Cardiff University, London, United Kingdom

- 245 IMPROVED LENGTH OF STAY FOR RA-RELATED ORTHOPAEDIC SURGERY OVER THE PAST 25 YEARS IS RELATED TO DISEASE MARKERS: A COMPARISON OF NATIONAL DATA WITH TWO UK COHORTS: 1986-2012**
Elena Nikiphorou¹, Stephen Morris², David James³, Patrick Kiely⁴, David Walsh^{5,6}, Adam Young¹

¹ERAS, Rheumatology, St Albans City Hospital, St Albans, United Kingdom; ²Research Department of Epidemiology and Public Health, University College London, London, United Kingdom; ³Rheumatology, Diana Princess of Wales Hospital, Grimsby, United Kingdom; ⁴Rheumatology, St George's Healthcare NHS Trust, London, United Kingdom; ⁵Rheumatology, Sherwood Forest Hospitals NHS Trust, Sutton-in-Ashfield, United Kingdom; ⁶Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom

- 246 MAKE IT HAPPEN, IMPLEMENTING A DMARDS MONITORING SERVICE REDESIGN**
Ernest C. Wong¹, Julie Long¹, Alex Fletcher¹, Margaret Fletcher¹, Simon Holmes², Peter Hockey³

¹Rheumatology, Queen Alexandra Hospital, Portsmouth, United Kingdom; ²Queen Alexandra Hospital, Portsmouth, United Kingdom; ³South Central SHA, Newbury, United Kingdom

MISCELLANEOUS RHEUMATIC DISEASES

- 247 IS OSMIUM SYNOVECTOMY USEFUL? A RETROSPECTIVE OUTCOME AUDIT**
Mohsin Abbas¹, C. Chattopadhyay¹

¹Rheumatology, Lincoln County Hospital, Lincoln, United Kingdom

- 248 A SYSTEMATIC ANALYSIS OF THE SAFETY OF PRESCRIBING OF ANTI-RHEUMATIC, IMMUNOSUPPRESSIVE AND BIOLOGIC DRUGS IN MEN TRYING TO CONCEIVE**
Julia Flint¹, Mary Gayed², Karen Schreiber³, Subha Arthanari⁴, Mohamed Nisar⁴, Munther Khamashta³, Caroline Gordon², Ian Giles¹

¹Rheumatology, University College London, London, United Kingdom; ²Rheumatology, Division of Infection and Immunity, The Medical School, University of Birmingham, Birmingham, United Kingdom; ³Rheumatology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; ⁴Rheumatology, Burton Hospitals NHS Foundation Trust, Burton-upon-Trent, United Kingdom

- 249 PREDICTORS OF AORTIC ANEURYSMS FOR GIANT CELL ARTERITIS SUBJECTS**
Joanna Robson¹, Amit Kiran¹, Joe Maskell², Nigel Arden^{1,2}, Andrew Hutchings³, Akan Emin⁴, David Culliford², Bhaskar Dasgupta⁵, William Hamilton⁶, Raashid Luqmani¹

¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom; ²MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom; ³London School of Hygiene and Tropical Medicine, London, United Kingdom; ⁴Clinical Effectiveness Unit, Royal College of Surgeons, London, United Kingdom; ⁵Southend Rheumatology Department, Southend University Hospital, Westcliff-on-Sea, United Kingdom; ⁶Peninsula Medical School, University of Exeter, Exeter, United Kingdom

250 THE PHENOTYPIC CONSEQUENCES OF MUTATIONS IN MORE THAN ONE GENE ASSOCIATED WITH AN INHERITED PERIODIC FEVER SYNDROME

Hannah Jethwa¹, Dorota Rowczenio², Hadija Trojer², Thirusa Russell², Jutta Loeffler², Philip Hawkins², Helen Lachmann²

¹NHS, London, United Kingdom; ²National Amyloidosis Centre, UCL, London, United Kingdom

251 AUTONOMIC NEUROPATHY IN RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS: PERIPHERAL SYMPATHETIC AND CARDIOVASCULAR AUTONOMIC FUNCTION ASSESSMENT

Inderjeet Verma^{1,2}, Ashit Syngle^{2,3}, Pawan Krishan¹, Nidhi Garg^{1,2}

¹Department of Pharmaceutical Sciences and Drug Research, Punjabi University Patiala, Punjab, India; ²Rheumatology, Healing Touch City Clinic, Chandigarh, India; ³Rheumatology, Fortis Multispecialty Hospital, Mohali, Punjab, India

252 A SYSTEMATIC ANALYSIS OF THE SAFETY OF PRESCRIBING OF ANTI-RHEUMATIC, IMMUNOSUPPRESSIVE AND BIOLOGIC DRUGS IN PREGNANT WOMEN WITH AUTOIMMUNE RHEUMATIC DISEASE

Julia Flint¹, Mary Gayed², Karen Schreiber³, Subha Arthanari⁴, Mohamed Nisar⁴, Munther Khamashta³, Caroline Gordon², Ian Giles¹

¹Rheumatology, University College London, London, United Kingdom; ²Rheumatology, Division of Immunity and Infection, The Medical School, University of Birmingham, Birmingham, United Kingdom; ³Rheumatology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; ⁴Rheumatology, Burton Hospitals NHS Foundation Trust, Burton-upon-Trent, United Kingdom

MUSCLE DISORDERS

253 SYSTEMATIC INVESTIGATION OF MOLECULAR MIMICRY CANDIDATES IN IDIOPATHIC INFLAMMATORY MYOPATHIES IDENTIFIES POTENTIAL NOVEL AUTOANTIGENS

Stephen P. McGowan¹, Dave T. Gerrard², Hector Chinoy^{3,4}, William E. Ollier^{1,3}, Robert G. Cooper³, Janine A. Lamb¹

¹CIGMR, Institute of Population Health, University of Manchester, Manchester, United Kingdom; ²Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Manchester, United Kingdom; ³The University of Manchester Rheumatic Diseases Centre, Salford Royal NHS Foundation Trust, Salford, United Kingdom; ⁴Musculoskeletal Centre, Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom

254 RETROSPECTIVE ANALYSIS OF THE OUTCOME OF PATIENTS WITH POLYMYOSITIS AND DERMATOMYOSITIS

Lucia Taborda¹, Pedro Correia Azevedo¹, David Isenberg¹

¹Rheumatology, University College London Hospitals, London, United Kingdom

OSTEOARTHRITIS: CLINICAL FEATURES

255 JOINT SPACE NARROWING OVER 5 YEARS PREDICTS FUTURE KNEE REPLACEMENTS UP TO FIFTEEN YEARS LATER

Kirsten M. Leyland¹, Amit Kiran¹, Andrew Judge^{1,2}, Dave Hunter¹, Debbie Hart³, Muhammad K. Javaid^{1,2}, Nigel Arden^{1,2}, Cyrus Cooper^{1,2}

¹NIHR Musculoskeletal BRU, University of Oxford, Oxford, United Kingdom; ²MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom; ³Department of Twin Research and Genetic Epidemiology, King's College London, London, United Kingdom

256 SELF-REPORTED AND CLINICAL OSTEOARTHRITIS ARE ASSOCIATED WITH LOW PHYSICAL PERFORMANCE ACROSS SIX COUNTRIES: THE EUROPEAN PROJECT ON OSTEOARTHRITIS

Mark H. Edwards¹, Anna E. Litwic¹, Karen A. Jameson¹, Dorly Deeg², Cyrus Cooper^{1,3}, Elaine Dennison¹

¹MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom;

²EMGO-Institute for Health and Care Research, VU University Medical Centre, Amsterdam, Netherlands;

³Institute of Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

257 SELF-REPORTED AND CLINICAL HAND OSTEOARTHRITIS ARE ASSOCIATED WITH LOW GRIP STRENGTH INDEPENDENT OF PAIN ACROSS SIX COUNTRIES: THE EUROPEAN PROJECT ON OSTEOARTHRITIS

Mark H. Edwards¹, Karen A. Jameson¹, Janet Cushnaghan¹, Avan Aihie Sayer¹, Dorly Deeg², Cyrus Cooper^{1,3}, Elaine Dennison¹

¹MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom;

²EMGO-Institute for Health and Care Research, VU University Medical Centre, Amsterdam, Netherlands;

³Institute of Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

258 DOES RADIOGRAPHIC OSTEOARTHRITIS PREDICT A SUBSEQUENT CLINICAL DIAGNOSIS OF KNEE OSTEOARTHRITIS? FINDINGS FROM THE HERTFORDSHIRE COHORT STUDY

Darshan Jagannath¹, Camille Parsons¹, Janet Cushnaghan¹, Cyrus Cooper^{1,2}, Mark H. Edwards¹, Elaine Dennison¹

¹MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom; ²Institute of Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

OSTEOARTHRITIS: PATHOGENESIS AND ANIMAL MODELS

259 STRUCTURAL ASSOCIATIONS OF PAIN IN PEOPLE WITH KNEE OSTEOARTHRITIS

Laura Stoppioello¹, Paul Mapp¹, Sadaf Ashraf¹, Deborah Wilson², Roger Hill², Brigitte Scammell^{1,3}, David Walsh^{1,2}

¹Arthritis Research UK Pain Centre, Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom; ²Department of Rheumatology, Sherwood Forest Hospitals NHS Foundation Trust, Sutton-in-Ashfield, United Kingdom; ³Division of Orthopaedic and Accident Surgery, University of Nottingham, Nottingham, United Kingdom

260 MAGNETIC RESONANCE IMAGING AND HISTOLOGICAL ASSESSMENT OF BONE MARROW LESIONS IN THE OSTEOARTHRITIC HIP

Claire Wenham^{1,2}, Patricia Shore³, Richard Hodgson¹, Andrew Grainger¹, Jean Aaron³, Lesley Hordon³, Philip Conaghan^{1,2}

¹NIHR Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton Hospital, Leeds, United Kingdom; ²Section of Musculoskeletal Disease, Chapel Allerton Hospital, Leeds Institute for Molecular Medicine, Leeds, United Kingdom; ³School of Biomedical Sciences, University of Leeds, Leeds, United Kingdom

OSTEOARTHRITIS: TREATMENT

261 A 2-YEAR FOLLOW-UP STUDY ON THE EFFECT OF A FOOT-WORN BIOMECHANICAL DEVICE AND TREATMENT FOR REDUCED PAIN AND IMPROVED FUNCTION IN PATIENTS WITH KNEE OSTEOARTHRITIS

Yaron Bar-Ziv¹, Yiftah Beer¹, Yuvan Ran¹, Shaikhe Benedict¹, Nahum Halperin¹

¹The Department of Orthopedic Surgery, Assaf Harofeh Medical Centre, Zerifin, Israel

262 A NON-INVASIVE FOOT-WORN BIOMECHANICAL DEVICE AND TREATMENT FOR PATIENTS WITH HIP OSTEOARTHRITIS

Michael Drexler¹, Amit Mor², Ganit Segal², Amnon Lahad³, Amir Haim¹, Udi Rath¹, David M. Morgenstern⁴, Moshe Salai¹, Avi Elbaz²

¹Department of Orthopedic Surgery, Sourasky Medical Centre, Tel-Aviv, Israel; ²Research Department, Apos Therapy Research Group, Herzliya, Israel; ³Department of Family Medicine, Hebrew University and Clalit Health Services, Jerusalem, Israel; ⁴The Sports Medicine and Arthroscopy Unit, Hadassah Medical Centre, Mount Scopus, Jerusalem, Israel

263 SEQUENTIALLY PROGRAMMED MAGNETIC FIELD THERAPY: A NOVEL TREATMENT FOR OSTEOARTHRITIS: OUR EXPERIENCE

Vishwanath G. Vasishta^{1,2}

¹SBF Healthcare and Research Centre Pvt Ltd, Bangalore, India; ²Institute of Aerospace Medicine, Bangalore, India

SCLERODERMA AND RELATED DISORDERS

264 DIFFERENTIAL GENE EXPRESSION SIGNATURES IN RESIDENT LUNG FIBROBLASTS GOVERN SUSCEPTIBILITY OR RESISTANCE TO EXPERIMENTAL LUNG FIBROSIS



Emma Derrett-Smith¹, Rachel Hoyles¹, Korsia Khan¹, David J. Abraham¹, Christopher Denton¹

¹Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom

265 SEVERE GASTROINTESTINAL INVOLVEMENT IN SYSTEMIC SCLEROSIS IS FREQUENTLY ASSOCIATED WITH HAEMODYNAMICALLY SIGNIFICANT CARDIAC INVOLVEMENT

Amara Ezeonyeji¹, Gagandeep Takhar¹, Christopher Denton¹, Voon Ong¹

¹Centre for Rheumatology, Royal Free Hospital NHS Foundation Trust, London, United Kingdom

266 VIDEO-CAPILLAROSCOPY ASSESSMENT OF PERI-CALCINOTIC SKIN INDICATES SPECIFIC FEATURES OF SEVERE VASCULOPATHY ASSOCIATED WITH CALCIUM DEPOSITS IN SYSTEMIC SCLEROSIS



Lorraine Loughrey¹, Lesley-Anne Bissell¹, Elizabeth Hensor¹, Giuseppina Abignano¹, Anthony Redmond¹, Maya Buch¹, Francesco Del Galdo¹

¹Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom

267 A COMPARISON OF NEAR-INFRARED SPECTROSCOPY AND LASER DOPPLER FLOWMETRY AS TOOLS FOR ASSESSING SEVERITY OF HAND ISCHAEMIA IN SYSTEMIC SCLEROSIS



Frances C. Hall¹, Anshuman Malaviya^{1,2}, Muhammad Nisar^{1,3}, Sharon Baker⁴, Anita Furlong¹, Alison Mitchell¹, Anna L. Godfrey⁵, Michael Ruddlesden¹, Andreas Hadjinicolaou⁶

¹Rheumatology, Cambridge University Hospitals Foundation Trust, Cambridge, United Kingdom; ²Rheumatology, Bromfield Hospital, Chelmsford, United Kingdom; ³Rheumatology, Luton and Dunstable Hospital, Luton, United Kingdom; ⁴Clinical Research Facility, Cambridge University Hospitals Foundation Trust, Cambridge, United Kingdom; ⁵Haematology, Cambridge Institute for Medical Research, Cambridge, United Kingdom; ⁶School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom

268 A WEB-BASED STUDY COMPARING VIDEOCAPILLAROSCOPY AND DERMOSCOPY IN THE ASSESSMENT OF NAILFOLD CAPILLARIES IN PATIENTS WITH SYSTEMIC-SCLEROSIS SPECTRUM DISORDERS



Michael Hughes¹, Tonia Moore¹, Neil O'Leary², Andrew Tracey¹, Holly Ennis¹, Graham Dinsdale¹, Christopher Roberts², Ariane Herrick¹

¹Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Salford Royal NHS Foundation Trust, Salford, United Kingdom; ²Centre for Biostatistics, Institute of Population Health, The University of Manchester, Manchester, United Kingdom

269 IMPACT OF DIGITAL ULCERS IN SCLERODERMA ON WORK AND DAILY ACTIVITIES: A SUBGROUP ANALYSIS OF UK PATIENTS ENROLLED IN THE DUO REGISTRY



Christopher P. Denton¹, Loic Guillevin², Elke Hunsche³, Daniel Rosenberg⁴, Barbara Schwierin³, Martin Scott⁵, Thomas Krieg⁶, Marina Anderson⁷, Frances C. Hall⁸, Ariane Herrick⁹, Neil McHugh¹⁰, Marco Matucci-Cerinic¹¹

¹Centre for Rheumatology, Royal Free Hospital, London, United Kingdom; ²Service de Médecine Interne, Paris Descartes University, Paris, France; ³Global Medical Science, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland; ⁴Epidemiology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland; ⁵Statistics, Numerus Ltd, Wokingham, United Kingdom; ⁶Department of Dermatology, University of Cologne, Cologne, Germany; ⁷Academic Rheumatology Unit, University Hospital Aintree, Liverpool, United Kingdom; ⁸Sidney Sussex College, Cambridge University Hospitals Foundation Trust, Cambridge, United Kingdom; ⁹Rheumatology, University of Manchester, Manchester, United Kingdom; ¹⁰Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom; ¹¹Department of Medicine, University of Florence, Florence, Italy

270 IL6 AND CCL2 CO-REGULATE FIBROBLAST-DEPENDENT TRANSENDOTHELIAL MIGRATION OF MONONUCLEAR CELLS AND FIBROTIC RESPONSE IN SCLERODERMA

Rebecca Alade¹, Korsia Khan¹, Shiwen Xu¹, Christopher Denton¹, Voon Ong¹

¹Centre for Rheumatology and Connective Tissue Diseases, University College London Medical School Royal Free Campus, London, United Kingdom

271 ORGAN-BASED COMPLICATIONS AND SURVIVAL IN MALE AND FEMALE PATIENTS WITH SYSTEMIC SCLEROSIS

Svetlana Nihtyanova¹, Voon Ong¹, Christopher P. Denton¹

¹Centre for Rheumatology and Connective Tissue Diseases, University College London Medical School, Royal Free Campus, London, United Kingdom

272 ALTERED EXPRESSION OF P2X7 RECEPTOR IN THE EPIDERMIS OF DIFFUSE SCLERODERMA PATIENTS



Kristina E. Clark¹, Frederick W. K. Tam², Robert Unwin³, Korsia Khan¹, David J. Abraham¹, Christopher Denton¹, Richard J. Stratton¹

¹Royal Free and Centre for Rheumatology and Connective Tissue Diseases, Royal Free Hospital Campus, University College Medical School, University College London, London, United Kingdom; ²Imperial College Kidney and Transplant Institute, Hammersmith Hospital, London, United Kingdom; ³University College London Centre for Nephrology, Royal Free Campus and Hospital, University College London, London, United Kingdom

273 INCIDENCE AND PREDICTORS OF PULMONARY COMPLICATIONS IN SYSTEMIC SCLEROSIS



Svetlana Nihtyanova¹, Benjamin Schreiber², Voon Ong¹, Christopher P. Denton¹

¹Centre for Rheumatology and Connective Tissue Diseases, University College London Medical School, Royal Free Campus, London, United Kingdom; ²Pulmonary Hypertension Service, Royal Free Hospital, London, United Kingdom

SJÖGREN'S SYNDROME AND OTHER CONNECTIVE TISSUE DISORDERS

274 AN UNUSUAL COMPLICATION OF RITUXIMAB: SEVERE CMV COLITIS IN PRIMARY SJÖGREN'S TREATED WITH A SINGLE CYCLE OF RITUXIMAB



Chong Seng Edwin Lim¹, Bhaskar Dasgupta¹

¹Rheumatology, Southend University Hospital NHS Foundation Trust, Prittlewell Chase, Westcliff-on-Sea, United Kingdom

275 ACCUMULATION OF CIRCULATING AUTOACTIVE NAÏVE B CELLS REVEAL DEFECTS OF EARLY B-CELL TOLERANCE CHECKPOINTS IN PATIENTS WITH SJÖGREN'S SYNDROME

Elisa Corsiero¹, Nurhan Sutcliffe¹, Hedda Wardemann², Costantino Pitzalis¹, Michele Bombardieri¹

¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, London, United Kingdom; ²Molecular Immunology Group, Max Planck Institute for Infection Biology, Berlin, Germany

SOFT TISSUE AND REGIONAL MUSCULOSKELETAL DISEASE, FIBROMYALGIA

276 A PHASE IV PILOT STUDY TO ESTABLISH IF AN INTRAMUSCULAR STEROID INJECTION IS AS EFFECTIVE AS AN INTRALESIONAL STEROID INJECTION IN THE TREATMENT OF TENNIS ELBOW?

Hasan Tahir¹, Simon Donnelly¹, Mandy Greenwood¹

¹Rheumatology, Barts Health NHS Trust, Whipps Cross University Hospital, London, United Kingdom

277 THE RELATIONSHIP BETWEEN BENIGN JOINT HYPERMOBILITY SYNDROME AND PSYCHOLOGICAL FEATURES: A SYSTEMATIC REVIEW AND META-ANALYSIS

Toby O. Smith¹, Vicky Easton², Holly Bacon², Emma Jerman³, Kate Armon^{1,2}, Fiona Poland¹, Alex Macgregor¹

¹Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, United Kingdom; ²Jenny Lind Hospital, Norfolk and Norwich University Hospital, Norwich, United Kingdom; ³Paediatric Occupational Therapy Team, Norwich Community Health and Care NHS Trust, Norwich, United Kingdom

SPONDYLARTHROPATHIES (INCLUDING PSORIATIC ARTHRITIS)

278 REFERRAL PATTERNS AND DIAGNOSIS OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS OF AN INTERNATIONAL SURVEY

Desiree van der Heijde¹, Joachim Sieper², Dirk Elewaut³, Aileen L. Pagan⁴, Dianne Nguyen⁵

¹Rheumatology Department, Leiden University Medical Centre, Leiden, Netherlands; ²Rheumatology Department, Charité Universitätsmedizin Berlin, Berlin, Germany; ³Department of Rheumatology, Ghent University Hospital, Ghent, Belgium; ⁴Immunology Development, AbbVie, North Chicago, IL, USA; ⁵Medical Affairs, AbbVie, Rungis, France

279 THE ARTHRITIS NEW ZEALAND ANKYLOSING SPONDYLITIS AWARENESS CAMPAIGN AND ITS EFFECTS ON RATES OF REFERRAL TO RHEUMATOLOGY SERVICES

Christoffel Badenhorst¹, Sandra Kirby², Douglas White³, Andrew Harrison⁴, Jose A. Garcia⁵, Simon Stebbings¹

¹Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, ²Arthritis New Zealand, Wellington, ³Department of Rheumatology, Waikato Hospital, Hamilton, ⁴Department of Medicine, Wellington School of Medicine, University of Otago, Dunedin and ⁵Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand

280 CORRELATION BETWEEN CLINICAL AND MRI DISEASE ACTIVITY SCORES IN AXIAL SPONDYLOARTHRITIS

James W. MacKay¹, Sharief Aboelmagd¹, Karl Gaffney²


¹Radiology, Norfolk and Norwich University Hospital, Norwich, United Kingdom; ²Rheumatology, Norfolk and Norwich University Hospital, Norwich, United Kingdom

281 ACHIEVING ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE C-REACTIVE PROTEIN MAJOR IMPROVEMENT AND INACTIVE DISEASE IN PATIENTS WITH ANKYLOSING SPONDYLITIS AFTER TREATMENT WITH GOLIMUMAB IS ASSOCIATED WITH NORMALIZED HEALTH-RELATED QUALITY OF LIFE: 2-YEAR RESULTS FROM GO-RAISE

Desiree van der Heijde¹, Atul Deodhar², Jurgen Braun³, Michael Mack⁴, Ben Hsu⁵, Tim Gathany⁶, Chenglong Han⁶, Robert D. Inman⁷

¹Rheumatology, Leiden University Medical Centre, Leiden, Netherlands; ²Rheumatology, Oregon Health and Science University, Portland, OR, USA; ³Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany; ⁴Biostatistics, Janssen Research and Development, LLC., Spring House, PA, USA; ⁵Immunology, Janssen Research and Development, LLC., Spring House, PA, USA; ⁶Health Economics, Janssen Global Services, LLC., Malvern, PA, USA; ⁷Rheumatology, University of Toronto, Toronto, ON, Canada



282 DISEASE SEVERITY AND MOOD DISTURBANCE IN ANKYLOSING SPONDYLITIS: A PROSPECTIVE STUDY 

Nicola Cooper-Moss¹, Jonathan Packham^{1,2}, Vicky Strauss¹

¹Arthritis Research UK Primary Care Centre, Keele University, Keele, United Kingdom; ²Haywood Rheumatology Centre, Haywood Hospital, Burslem, United Kingdom

283 IS THERE SUB-CLINICAL JOINT DISEASE IN EARLY PSORIATIC ARTHRITIS? A CLINICAL COMPARISON WITH POWER DOPPLER ULTRASOUND

Jane E. Freeston¹, Laura Coates¹, Jackie Nam¹, Anna R. Moverley¹, Philip Helliwell¹, Elizabeth Hensor¹, Richard Wakefield¹, Paul Emery¹, Philip Conaghan¹

¹Division of Rheumatic and MSK Disease, University of Leeds, Leeds, United Kingdom

284 EFFECT OF CERTOLIZUMAB PEGOL ON SIGNS/SYMPTOMS IN PATIENTS WITH PSORIATIC ARTHRITIS WITH/WITHOUT PRIOR ANTI-TNF EXPOSURE: 24-WEEK RESULTS OF A PHASE III DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED STUDY


P. Mease¹, R. Fleischmann², J. Wollenhaupt³, A. Deodhar⁴, D. Kielar⁵, F. Woltering⁶, C. Stach⁶, B. Hoepken⁶, T. Arledge⁷, Desiree van der Heijde⁸

¹Swedish Medical Centre and University of Washington, Seattle, WA, USA; ²University of Texas SW Medical Centre, Dallas, TX, USA; ³Schoen Klinik, Hamburg, Germany; ⁴Oregon Health and Science University, Portland, OR, USA; ⁵UCB Pharma, Brussels, Belgium; ⁶UCB Pharma, Monheim am Rhein, Germany; ⁷UCB Pharma, Raleigh, NC, USA; ⁸Department of Rheumatology, Leiden University Medical Centre, Leiden, Netherlands

285 EFFECT OF CERTOLIZUMAB PEGOL ON THE MULTIPLE FACETS OF PSORIATIC ARTHRITIS AS REPORTED BY PATIENTS: 24-WEEK PATIENT-REPORTED OUTCOME RESULTS OF A PHASE III DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED STUDY


D. Gladman¹, R. Fleischmann², G. Coteur³, F. Woltering⁴, P. Mease⁵

¹Division of Health Care and Outcomes Research, Toronto Western Research Institute Toronto Western Hospital, Toronto, ON, Canada; ²Metroplex Clinical Research Centre, Dallas, TX, USA; ³UCB Pharma, Brussels, Belgium; ⁴UCB Pharma, Monheim-am-Rhein, Germany; ⁵Swedish Medical Centre and University of Washington, Seattle, WA, USA

286 IMPROVEMENTS IN PRODUCTIVITY AT PAID WORK AND WITHIN HOUSEHOLD, AND INCREASED PARTICIPATION IN DAILY ACTIVITIES AFTER 24 WEEKS OF CERTOLIZUMAB PEGOL TREATMENT OF PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS OF A PHASE III DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED STUDY 

Arthur Kavanaugh¹, D. Gladman², Desiree van der Heijde³, O. Purcaru⁴, P. Mease⁵

¹Division of Rheumatology Allergy and Immunology, UCSD, San Diego, CA, USA; ²Division of Health Care and Outcomes Research, Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada; ³Department of Rheumatology, Leiden University Medical Centre, Leiden, Netherlands; ⁴UCB Pharma, Brussels, Belgium; ⁵Swedish Medical Centre and University of Washington, Seattle, WA, USA

287 USTEKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS OF THE PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PSUMMIT I STUDY 

Iain McInnes¹, Arthur Kavanaugh², Alice B. Gottlieb³, Lluis Puig⁴, Proton Rahman⁵, Christopher Ritchlin⁶, Shu Li⁷, Yuhua Wang⁷, Alan Mendelsohn⁸, Mittie Doyle^{8,9}

¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom; ²Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, CA, USA; ³Dermatology, Tufts Medical Centre, Boston, MA, USA; ⁴Dermatology, Universitat Autònoma de Barcelona, Barcelona, Spain; ⁵Rheumatology, Memorial University, St. John's, NF, Canada; ⁶Division of Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, USA; ⁷Biostatistics, Janssen Research and Development, LLC., Spring House, PA, USA; ⁸Immunology, Janssen Research and Development, LLC., Spring House, PA, USA; ⁹Rheumatology, University of Pennsylvania, Philadelphia, PA, USA

288 THE FEASIBILITY, RELIABILITY AND SENSITIVITY TO CHANGE OF FOUR RADIOGRAPHIC SCORING METHODS IN PATIENTS WITH PSORIATIC ARTHRITIS

William Tillett¹, Deepak Jadon¹, Gavin Shaddick², Charlotte Cavill³, Graham Robinson⁴, Raj Sengupta¹, Eleanor Korendowych¹, Corinne de Vries⁵, Neil McHugh^{1,5}

¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom; ²Department of Mathematics, University of Bath, Bath, United Kingdom; ³Rheumatology, Bath Institute for Rheumatic Diseases, Bath, United Kingdom; ⁴Radiology, Royal United Hospital, Bath, United Kingdom; ⁵Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom

289 THE ROLE OF BIOMECHANICAL-RELATED FACTORS IN ANKYLOSING SPONDYLITIS AS ASSESSED BY REPORTED EFFECTS OF EXERCISE FROM PHYSIOTHERAPY AND SPORTING PARTICIPATION: RESULTS FROM A NATIONAL PATIENT SURVEY



Rebecca C. Thomas¹, Toshihide Shuto², Noemi Busquets-Peréz³, Helena Marzo-Ortega¹, Dennis McGonagle¹

¹Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, UK, ²Department of Rheumatology and Orthopaedics, Chiyoda Hospital, Miyazaki, Japan and ³Department of Rheumatology, Hospital General de Granollers, Barcelona, Spain

290 CROSS-SECTIONAL STUDY OF WORK DISABILITY IN SPONDYLOARTHRITIS USING THE WPAI-SPA

William Tillett¹, Gavin Richards¹, Charlotte Cavill², Raj Sengupta¹

¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom; ²Rheumatology, Bath Institute for Rheumatic Diseases, Bath, United Kingdom

291 CASELOAD AND IMPACT OF THE LEEDS COMBINED RHEUMATOLOGY AND GASTROENTEROLOGY CLINIC

Toshihide Shuto¹, Helena Marzo-Ortega², Rebecca C. Thomas², Sarah Bingham³, Laura Coates², Paul Emery², P. John Hamlin⁴

¹Department of Rheumatology and Orthopaedics, Chiyoda Hospital, Miyazaki, Japan; ²Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom; ³Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom; ⁴Department of Gastroenterology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

292 EARLY INFLAMMATORY BACK PAIN SERVICE TO PROVIDE ASSESSMENT, DIAGNOSIS AND PROMPT TREATMENT FOR PATIENTS WITH AXIAL SPONDYLOARTHROPATHIES

Susannah Cambridge¹, Hasan Tahir¹, Simon Donnelly¹, Rebecca A. Adshead¹

¹Rheumatology, Whipps Cross Hospital, Barts Health NHS Trust, London, United Kingdom

293 AN ASSOCIATION BETWEEN PERIODONTAL DISEASE, ORAL HEALTH RELATED QUALITY OF LIFE AND DISEASE ACTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS

Praema Suppiah¹, Mary Cullinan¹, Anita Nolan¹, W. M. Thompson¹, Simon Stebbings²

¹School of Dentistry, University of Otago, Dunedin, New Zealand; ²Department of Medicine, Dunedin School of Medicine, Dunedin, New Zealand

294 IS THERE CLINICAL VALUE TO ANA MONITORING IN ANKYLOSING SPONDYLITIS PATIENTS TREATED WITH INFlixIMAB? A RETROSPECTIVE AUDIT OF 70 PATIENTS

Hannah R. Mathieson¹, Sarah L. Mackie², Domini Bryer¹, Maya Buch^{1,2}, Paul Emery^{1,2}, Helena Marzo-Ortega^{1,2}

¹Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom; ²Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom

295 ANKYLOSING SPONDYLITIS: ARE WE DOING ENOUGH TO ASSESS FOR OSTEOPOROSIS AND DOES VITAMIN D MATTER IN THIS PATIENT GROUP?



Maria Krutikov¹, Leanne Gray¹, Ellen Bruce¹, Pauline Ho¹

¹Kellgren Centre for Rheumatology, Manchester Royal Infirmary, Manchester, United Kingdom

296 TNF INHIBITORS IN AXIAL SPA/EARLY AS: TIME FOR A SHAKE-UP, IS NICE LISTENING?

Helena Marzo-Ortega¹, Noemi Busquets-Peréz²,
Rebecca C. Thomas¹, Karl Gaffney³, Andrew Keat⁴

¹Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom; ²Department of Rheumatology, Hospital General de Granollers, Barcelona, Spain; ³Department of Rheumatology, Norfolk and Norwich University Hospital, Norwich, United Kingdom; ⁴Department of Rheumatology, Northwick Park Hospital, London, United Kingdom

297 A PILOT STUDY TO SCREEN PATIENTS PRESENTING TO EYE CASUALTY WITH UVEITIS FOR SYMPTOMS OF UNDIAGNOSED SPONDYLOARTHRITIS



William Innes¹, Ranjeet Pandit¹, Lesley Kay²

¹Ophthalmology Department, The Newcastle Hospitals NHS Foundation Trust, Newcastle, United Kingdom;
²Musculoskeletal Directorate, The Newcastle Hospitals NHS Foundation Trust, Newcastle, United Kingdom

298 EXPERIENCE AND EFFECTIVENESS OF EDUCATIONAL PROGRAMS FOR PRIMARY CARE PHYSICIANS FOR EARLY DIAGNOSIS OF ANKYLOSING SPONDYLITIS IN KAZAN, RUSSIAN FEDERATION

Svetlana Lapshina¹, Leysan Myasoutova¹, Shandor Erdes²

¹Kazan State Medical University, Kazan, Russian Federation;
²Rheumatology, Institution of Rheumatology RAMN, Moscow, Russian Federation

299 TNF INHIBITORS IN PSORIATIC ARTHRITIS: EFFECTS ON NAIL DISEASE: AN OBSERVATIONAL STUDY



Dinny Wallis¹, Nicola Waldron¹, Neil McHugh¹,
Eleanor Korendowych¹

¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

300 "BASDAI CREEP": CHANGING PERCEPTIONS OF SYMPTOMS DESPITE SUSTAINED TREATMENT EFFICACY?

Iona Thorne¹, Claire Harris¹, Andrew Keat¹

¹Northwick Park Hospital, London, United Kingdom

301 SPIRONOLACTONE IMPROVES ENDOTHELIAL DYSFUNCTION IN ANKYLOSING SPONDYLITIS

Nidhi Garg¹, Ashit Syngle², Kanchan Vohra¹,
Dinesh Khinchi¹, Inderjeet Verma¹, Ladbans Kaur³

¹Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India; ²Rheumatology, Healing Touch City Clinic, Chandigarh, India; ³Radiology, Prime Diagnostics, Chandigarh, India

302 TIME TO DIAGNOSIS IN AXIAL SPONDYLARTHRTIS: A RETROSPECTIVE STUDY OF MILITARY PERSONNEL

Alexis Jones¹, Nikki Harrison¹, Denise Harris¹ Tim Jones¹,
Jon Rees¹, Alex Bennett¹

¹Rheumatology and Rehab, DMRC Headley Court, Epsom, United Kingdom

303 DOES VITAMIN D STATUS AFFECT DISEASE ACTIVITY OR FUNCTIONALITY IN AS



Shahid Fazal¹, Nicola Tugnet², Nick Barkham²

¹Rheumatology, University Hospital Coventry and Warwick NHS Trust, Coventry, United Kingdom; ²Rheumatology, Royal Wolverhampton Hospitals NHS trust, Coventry, United Kingdom

VASCULITIS

304 EXPLAINING FATIGUE IN ANCA-ASSOCIATED VASCULITIS

Neil Basu¹, Andrew McClean², Lorraine Harper², Esther N. Amft³, Neeraj Dhaun⁴, Raashid A. Luqmani⁵, Mark A. Little⁶, David R. Jayne⁷, Oliver Flossmann⁸, John McLaren⁹, Vinod Kumar¹⁰, David M. Reid¹, Gary J. Macfarlane¹, Gareth Jones¹

¹Musculoskeletal Collaboration, School of Medicine and Dentistry, University of Aberdeen, Aberdeen, United Kingdom; ²School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom; ³Rheumatology, Western General Hospital, Edinburgh, United Kingdom; ⁴Renal Medicine, Edinburgh Royal Infirmary, Edinburgh, United Kingdom; ⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom; ⁶Trinity Health Kidney Centre, Trinity College Dublin, Dublin, Ireland; ⁷Clinical Medicine, Addenbrooke's Hospital, Cambridge, United Kingdom; ⁸Renal Unit, Royal Berkshire Hospital, Reading, United Kingdom; ⁹Rheumatic Diseases Unit, Whyteman's Brae Hospital, Kirkcaldy, United Kingdom; ¹⁰Rheumatology, Ninewells Hospital, Dundee, United Kingdom

305 GIANT CELL ARTERITIS: OVER-DIAGNOSED?

Max Yates^{1,2}, Richard A. Watts^{2,3}, Laszlo Igali⁴, Chetan Mukhtyar¹, Alex Macgregor^{1,2}

¹Rheumatology, Norfolk and Norwich University Hospital, Norwich, United Kingdom; ²Norwich Medical School, University of East Anglia, Norwich, United Kingdom; ³Rheumatology, Ipswich Hospital, Ipswich, United Kingdom; ⁴Histopathology, Norfolk and Norwich University Hospital, Norwich, United Kingdom

306 TREATMENT-RELATED DAMAGE IN THE ANCA-ASSOCIATED VASCULITIDES: AN ANALYSIS OF THE EUROPEAN VASCULITIS STUDY GROUP THERAPEUTIC TRIALS

Joanna Robson¹, Helen Doll², Stephen Yew³, Oliver Flossmann³, Ravi Suppiah¹, Lorraine Harper⁴, Peter Hoggund⁵, David Jayne³, Chetan Mukhtyar⁶, Kerstin Westman⁵, Raashid Luqmani¹

¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom; ²Rheumatology, University of East Anglia, Norwich, United Kingdom; ³Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, United Kingdom; ⁴Renal Department, University of Birmingham, Birmingham, United Kingdom; ⁵Renal Department, Lund University, Lund, Sweden; ⁶Rheumatology Department, Norfolk and Norwich University Hospital, Norwich, United Kingdom

307 FAST-TRACK PATHWAY REDUCES VISION LOSS IN GIANT CELL ARTERITIS

Win Win Maw¹, Pravin Patil¹, Mark Williams¹, Tochukwa Adizie¹, Dimitrios Christidis¹, Frances Borg¹, Bhaskar Dasgupta¹, Alexander Robertson¹

¹Rheumatology, Southend University Hospital, Southend on Sea, United Kingdom

308 SUCCESSFUL PREGNANCY OUTCOMES IN PATIENTS WITH ANCA VASCULITIS

Adam P. Croft¹, Stuart Smith¹, S. Carr², S. Youssouf², A. Salama³, C. Pusey⁴, L. Harper¹, M. Morgan¹

¹Centre for Translational Inflammation Research, University of Birmingham, Birmingham, United Kingdom; ²Department of Nephrology, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom; ³Centre for Nephrology, University College London, London, United Kingdom; ⁴Department of Medicine, Imperial College London, London, United Kingdom